WO2001034152A1 - Gouttes nasales contenant des derives de pyridazine condenses - Google Patents
Gouttes nasales contenant des derives de pyridazine condenses Download PDFInfo
- Publication number
- WO2001034152A1 WO2001034152A1 PCT/JP2000/007719 JP0007719W WO0134152A1 WO 2001034152 A1 WO2001034152 A1 WO 2001034152A1 JP 0007719 W JP0007719 W JP 0007719W WO 0134152 A1 WO0134152 A1 WO 0134152A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ethyl acetate
- added
- mixture
- pyridazine
- Prior art date
Links
- 239000007923 nasal drop Substances 0.000 title claims abstract description 13
- 229940100662 nasal drops Drugs 0.000 title claims abstract description 10
- 150000004892 pyridazines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 225
- 150000003839 salts Chemical class 0.000 claims abstract description 90
- 125000003118 aryl group Chemical group 0.000 claims abstract description 29
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 19
- 229940002612 prodrug Drugs 0.000 claims abstract description 19
- 239000000651 prodrug Substances 0.000 claims abstract description 19
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 14
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 14
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 6
- -1 diphenylmethoxy Chemical group 0.000 claims description 227
- 125000000217 alkyl group Chemical group 0.000 claims description 122
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 103
- 125000001424 substituent group Chemical group 0.000 claims description 86
- 238000002360 preparation method Methods 0.000 claims description 83
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 66
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 66
- 125000005843 halogen group Chemical group 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
- 125000006308 propyl amino group Chemical group 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 42
- 229910052757 nitrogen Inorganic materials 0.000 claims description 37
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 31
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 29
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 21
- 125000002252 acyl group Chemical group 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 8
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 6
- 230000001387 anti-histamine Effects 0.000 claims description 5
- 239000000043 antiallergic agent Substances 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 3
- 150000004683 dihydrates Chemical class 0.000 claims description 2
- 210000003979 eosinophil Anatomy 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000003399 chemotactic effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 970
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 321
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 248
- 239000000203 mixture Substances 0.000 description 246
- 230000002829 reductive effect Effects 0.000 description 214
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 210
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 144
- 238000001816 cooling Methods 0.000 description 135
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 127
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 124
- 235000019341 magnesium sulphate Nutrition 0.000 description 124
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 120
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 103
- 235000002639 sodium chloride Nutrition 0.000 description 103
- 238000010898 silica gel chromatography Methods 0.000 description 99
- 239000005457 ice water Substances 0.000 description 93
- 239000013078 crystal Substances 0.000 description 84
- 238000000921 elemental analysis Methods 0.000 description 79
- 239000000243 solution Substances 0.000 description 79
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
- 125000003545 alkoxy group Chemical group 0.000 description 75
- 238000010992 reflux Methods 0.000 description 69
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 67
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 64
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 61
- 238000001914 filtration Methods 0.000 description 60
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 60
- 238000004519 manufacturing process Methods 0.000 description 59
- 238000002844 melting Methods 0.000 description 59
- 230000008018 melting Effects 0.000 description 59
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 58
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 57
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 53
- 238000006243 chemical reaction Methods 0.000 description 50
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 48
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 42
- 238000004458 analytical method Methods 0.000 description 38
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 36
- 150000002430 hydrocarbons Chemical group 0.000 description 30
- 229910000027 potassium carbonate Inorganic materials 0.000 description 30
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 30
- 239000001530 fumaric acid Substances 0.000 description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 29
- 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 26
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 26
- 229910000104 sodium hydride Inorganic materials 0.000 description 26
- 239000012312 sodium hydride Substances 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 24
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
- 230000008569 process Effects 0.000 description 23
- 239000012267 brine Substances 0.000 description 22
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 125000000753 cycloalkyl group Chemical group 0.000 description 21
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 21
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 21
- 125000003282 alkyl amino group Chemical group 0.000 description 20
- 125000002947 alkylene group Chemical group 0.000 description 19
- 239000000460 chlorine Substances 0.000 description 19
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 19
- 239000012141 concentrate Substances 0.000 description 18
- OQAOREVBRZVXDS-UHFFFAOYSA-N 4-benzhydryloxypiperidine Chemical compound C1CNCCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OQAOREVBRZVXDS-UHFFFAOYSA-N 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 17
- 235000008504 concentrate Nutrition 0.000 description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 16
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 15
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 14
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 14
- 125000004414 alkyl thio group Chemical group 0.000 description 13
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 12
- 229910052794 bromium Inorganic materials 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 12
- 229910052708 sodium Inorganic materials 0.000 description 12
- 229940083542 sodium Drugs 0.000 description 12
- 235000015424 sodium Nutrition 0.000 description 12
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 11
- ILKSBSWZWUODQX-UHFFFAOYSA-N [1,2,4]triazolo[1,5-b]pyridazine Chemical compound C1=CC=NN2N=CN=C21 ILKSBSWZWUODQX-UHFFFAOYSA-N 0.000 description 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 239000011737 fluorine Substances 0.000 description 11
- 229910052731 fluorine Inorganic materials 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- AKAGLBBCCXXHAA-UHFFFAOYSA-N 6-chloro-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(Cl)C=CC2=NC=NN21 AKAGLBBCCXXHAA-UHFFFAOYSA-N 0.000 description 10
- 201000004624 Dermatitis Diseases 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 9
- 239000004215 Carbon black (E152) Substances 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 229930195733 hydrocarbon Natural products 0.000 description 9
- 125000002950 monocyclic group Chemical group 0.000 description 9
- 125000004043 oxo group Chemical group O=* 0.000 description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 8
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 208000002205 allergic conjunctivitis Diseases 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 8
- 239000011630 iodine Substances 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 8
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 8
- 235000009518 sodium iodide Nutrition 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 7
- 125000005530 alkylenedioxy group Chemical group 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 7
- LDTLDBDUBGAEDT-UHFFFAOYSA-N methyl 3-sulfanylpropanoate Chemical compound COC(=O)CCS LDTLDBDUBGAEDT-UHFFFAOYSA-N 0.000 description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 7
- SYSATALHMMDBPP-WLHGVMLRSA-N (e)-but-2-enedioic acid;pyridazine Chemical compound C1=CC=NN=C1.OC(=O)\C=C\C(O)=O SYSATALHMMDBPP-WLHGVMLRSA-N 0.000 description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 206010010741 Conjunctivitis Diseases 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- GQTKRYRXYDIDFX-UHFFFAOYSA-N [1,2,4]triazolo[1,5-b]pyridazine dihydrochloride Chemical compound Cl.Cl.N=1C=NN2N=CC=CC21 GQTKRYRXYDIDFX-UHFFFAOYSA-N 0.000 description 5
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 5
- 150000008046 alkali metal hydrides Chemical class 0.000 description 5
- 208000024998 atopic conjunctivitis Diseases 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- JCRUBWCYIOZELU-UHFFFAOYSA-N ethyl 2-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropanoate Chemical compound N1=C(Cl)C=CC2=NC(C(C)(C)C(=O)OCC)=CN21 JCRUBWCYIOZELU-UHFFFAOYSA-N 0.000 description 5
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 5
- 229940080818 propionamide Drugs 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 150000003462 sulfoxides Chemical class 0.000 description 5
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
- FOZVXADQAHVUSV-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)ethane Chemical compound BrCCOCCBr FOZVXADQAHVUSV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- XYGZNPKIOSSWBT-UHFFFAOYSA-N 6-chloro-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(Cl)C(C)=CC2=NC=NN21 XYGZNPKIOSSWBT-UHFFFAOYSA-N 0.000 description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 4
- ADITZEXDRVVYSS-UHFFFAOYSA-N C1(=CC=CC=C1)C(C1=CC=CC=C1)C1(N(CCNC1)C(C1=CC=CC=C1)C1=CC=CC=C1)C(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)C(C1=CC=CC=C1)C1(N(CCNC1)C(C1=CC=CC=C1)C1=CC=CC=C1)C(C1=CC=CC=C1)C1=CC=CC=C1 ADITZEXDRVVYSS-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 4
- 150000008041 alkali metal carbonates Chemical class 0.000 description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 229910000105 potassium hydride Inorganic materials 0.000 description 4
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 3
- QFNVCKHKFCXTLU-UHFFFAOYSA-N 2-([1,2,4]triazolo[1,5-b]pyridazin-6-yloxy)ethanol Chemical compound N1=C(OCCO)C=CC2=NC=NN21 QFNVCKHKFCXTLU-UHFFFAOYSA-N 0.000 description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- XKFMOQPABPTGHT-UHFFFAOYSA-N 6-(3-bromopropylsulfanyl)-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(SCCCBr)C=CC2=NC=NN21 XKFMOQPABPTGHT-UHFFFAOYSA-N 0.000 description 3
- IPUAYTXFSKDPFE-UHFFFAOYSA-N 6-[2-(2-bromoethoxy)ethylsulfanyl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(SCCOCCBr)C(C)=CC2=NC=NN21 IPUAYTXFSKDPFE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000001548 androgenic effect Effects 0.000 description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 150000001728 carbonyl compounds Chemical class 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000000311 contact blepharoconjunctivitis Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 230000013764 eosinophil chemotaxis Effects 0.000 description 3
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 3
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 3
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical group CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 125000005561 phenanthryl group Chemical group 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000003944 tolyl group Chemical group 0.000 description 3
- 125000005023 xylyl group Chemical group 0.000 description 3
- XLYMOEINVGRTEX-ONEGZZNKSA-N (e)-4-ethoxy-4-oxobut-2-enoic acid Chemical compound CCOC(=O)\C=C\C(O)=O XLYMOEINVGRTEX-ONEGZZNKSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- RBFXWRPOHHTWOU-UHFFFAOYSA-N 2-(3,6-dichloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropanoic acid Chemical compound C1=CC(Cl)=NN2C(Cl)=C(C(C)(C(O)=O)C)N=C21 RBFXWRPOHHTWOU-UHFFFAOYSA-N 0.000 description 2
- NVLTXLAYZCTRRV-UHFFFAOYSA-N 2-[2-(4-benzhydryloxypiperidin-1-yl)ethoxy]ethanol Chemical compound C1CN(CCOCCO)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 NVLTXLAYZCTRRV-UHFFFAOYSA-N 0.000 description 2
- GGMXLUZNIBEKQO-UHFFFAOYSA-N 2-[6-[3-(4-benzhydryloxypiperidin-1-yl)propoxy]-7-methylimidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoic acid Chemical compound CC1=CC2=NC(C(C)(C)C(O)=O)=CN2N=C1OCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 GGMXLUZNIBEKQO-UHFFFAOYSA-N 0.000 description 2
- NCLDPDHXFKOOBN-UHFFFAOYSA-N 2-[6-[3-(4-benzhydryloxypiperidin-1-yl)propoxy]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoic acid Chemical compound C1=CC2=NC(C(C)(C(O)=O)C)=CN2N=C1OCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 NCLDPDHXFKOOBN-UHFFFAOYSA-N 0.000 description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- UPMICOYKKFCFLK-UHFFFAOYSA-N 2-tert-butyl-6-chloro-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound C1=CC(Cl)=NN2N=C(C(C)(C)C)N=C21 UPMICOYKKFCFLK-UHFFFAOYSA-N 0.000 description 2
- KBOLQBLBQLGSPJ-UHFFFAOYSA-N 3-([1,2,4]triazolo[1,5-b]pyridazin-6-ylamino)propan-1-ol Chemical compound N1=C(NCCCO)C=CC2=NC=NN21 KBOLQBLBQLGSPJ-UHFFFAOYSA-N 0.000 description 2
- NZAGJZSHKTYYMN-UHFFFAOYSA-N 3-[tert-butyl(diphenyl)silyl]oxypropan-1-ol Chemical compound C=1C=CC=CC=1[Si](OCCCO)(C(C)(C)C)C1=CC=CC=C1 NZAGJZSHKTYYMN-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- CUPPNMQPYHEFHX-UHFFFAOYSA-N 6-[2-(2-bromoethoxy)ethylsulfanyl]-7-propan-2-yl-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(SCCOCCBr)C(C(C)C)=CC2=NC=NN21 CUPPNMQPYHEFHX-UHFFFAOYSA-N 0.000 description 2
- GEEZQWRJRSRBLK-UHFFFAOYSA-N 6-[2-(2-bromoethoxy)ethylsulfanyl]-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(SCCOCCBr)C=CC2=NC=NN21 GEEZQWRJRSRBLK-UHFFFAOYSA-N 0.000 description 2
- SZSHPXGCAGQBBW-UHFFFAOYSA-N 6-chloro-7-propan-2-yl-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(Cl)C(C(C)C)=CC2=NC=NN21 SZSHPXGCAGQBBW-UHFFFAOYSA-N 0.000 description 2
- MPZDNIJHHXRTIQ-UHFFFAOYSA-N 6-chloroimidazo[1,2-b]pyridazine Chemical compound N1=C(Cl)C=CC2=NC=CN21 MPZDNIJHHXRTIQ-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- TZQYKTAASGYBES-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.N=1C=NN2N=CC=CC21 Chemical compound C(\C=C\C(=O)O)(=O)O.N=1C=NN2N=CC=CC21 TZQYKTAASGYBES-WLHGVMLRSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241000721662 Juniperus Species 0.000 description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010037083 Prurigo Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- XBNPBPFXFACHRO-UHFFFAOYSA-N [1,2,4]triazolo[1,5-b]pyridazin-6-amine Chemical compound N1=C(N)C=CC2=NC=NN21 XBNPBPFXFACHRO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000002078 anthracen-1-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C([*])=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 2
- 125000000748 anthracen-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C([H])=C([*])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960004574 azelastine Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 235000010338 boric acid Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- NWVNXDKZIQLBNM-UHFFFAOYSA-N diphenylmethylpiperazine Chemical compound C1CNCCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NWVNXDKZIQLBNM-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 2
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- XLYMOEINVGRTEX-UHFFFAOYSA-N fumaric acid monoethyl ester Natural products CCOC(=O)C=CC(O)=O XLYMOEINVGRTEX-UHFFFAOYSA-N 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 229960004958 ketotifen Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HLWVKDCEODKPHW-UHFFFAOYSA-N propan-2-yl 2-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropanoate Chemical compound N1=C(Cl)C=CC2=NC(C(C)(C)C(=O)OC(C)C)=CN21 HLWVKDCEODKPHW-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 2
- WCKGRSPYFFVKQT-UHFFFAOYSA-N pyridazine;dihydrochloride Chemical compound Cl.Cl.C1=CC=NN=C1 WCKGRSPYFFVKQT-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 2
- 229910001948 sodium oxide Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- ABXYOVCSAGTJAC-JGWLITMVSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S ABXYOVCSAGTJAC-JGWLITMVSA-N 0.000 description 1
- LGOJDQXVTDMSCC-UHFFFAOYSA-N (6-chloroimidazo[1,2-b]pyridazin-2-yl) cyclopropanecarboxylate Chemical compound C1(CC1)C(=O)OC=1N=C2N(N=C(C=C2)Cl)C=1 LGOJDQXVTDMSCC-UHFFFAOYSA-N 0.000 description 1
- IPYWNMVPZOAFOQ-NABDTECSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;trihydrate Chemical compound O.O.O.S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 IPYWNMVPZOAFOQ-NABDTECSSA-N 0.000 description 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 1
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NGVRDROQJVZQMU-UHFFFAOYSA-N 1,1,1-tribromo-3-chloropropane Chemical compound ClCCC(Br)(Br)Br NGVRDROQJVZQMU-UHFFFAOYSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- KWPVLUWTOJHTFX-UHFFFAOYSA-N 1,3,3-trimethylpyrrolidin-2-one Chemical compound CN1CCC(C)(C)C1=O KWPVLUWTOJHTFX-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- FLOADUFBZDDTPV-UHFFFAOYSA-N 1,4-dibenzhydrylpiperazine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 FLOADUFBZDDTPV-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- KAJTYMCYKWVFGH-UHFFFAOYSA-N 1-(4-benzhydryloxypiperidin-1-yl)-3-([1,2,4]triazolo[1,5-b]pyridazin-6-yloxy)propan-2-ol Chemical compound C1=CC2=NC=NN2N=C1OCC(O)CN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 KAJTYMCYKWVFGH-UHFFFAOYSA-N 0.000 description 1
- KDLYARRYZGLMQB-UHFFFAOYSA-N 1-[6-[3-(4-benzhydryloxypiperidin-1-yl)propylamino]imidazo[1,2-b]pyridazin-2-yl]cyclopentane-1-carboxylic acid Chemical compound C=1N2N=C(NCCCN3CCC(CC3)OC(C=3C=CC=CC=3)C=3C=CC=CC=3)C=CC2=NC=1C1(C(=O)O)CCCC1 KDLYARRYZGLMQB-UHFFFAOYSA-N 0.000 description 1
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- HCVLSXREWLELBX-UHFFFAOYSA-N 1h-triazolo[1,5-b]pyridazine-2-carboxylic acid Chemical compound N1=CC=CC2=CN(C(=O)O)NN21 HCVLSXREWLELBX-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- AJILDJMHQKNBDW-UHFFFAOYSA-N 2-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropan-1-ol Chemical compound N1=C(Cl)C=CC2=NC(C(C)(CO)C)=CN21 AJILDJMHQKNBDW-UHFFFAOYSA-N 0.000 description 1
- RWNPEPGHBBUEPH-UHFFFAOYSA-N 2-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropanamide Chemical compound N1=C(Cl)C=CC2=NC(C(C)(C(N)=O)C)=CN21 RWNPEPGHBBUEPH-UHFFFAOYSA-N 0.000 description 1
- GWXBNPQQDLRKBZ-UHFFFAOYSA-N 2-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-n,n,2-trimethylpropanamide Chemical compound N1=C(Cl)C=CC2=NC(C(C)(C)C(=O)N(C)C)=CN21 GWXBNPQQDLRKBZ-UHFFFAOYSA-N 0.000 description 1
- KVLASLCXMVQZMN-UHFFFAOYSA-N 2-([1,2,4]triazolo[1,5-b]pyridazin-6-ylamino)ethanol Chemical compound N1=C(NCCO)C=CC2=NC=NN21 KVLASLCXMVQZMN-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- DNSJPQKXIQYJNA-UHFFFAOYSA-N 2-[6-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoic acid Chemical compound C1=CC2=NC(C(C)(C(O)=O)C)=CN2N=C1NCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 DNSJPQKXIQYJNA-UHFFFAOYSA-N 0.000 description 1
- YASUXVMOGKNGSN-UHFFFAOYSA-N 2-[6-[3-(4-benzhydryloxypiperidin-1-yl)propylamino]-7-methylimidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoic acid;dihydrochloride Chemical compound Cl.Cl.CC1=CC2=NC(C(C)(C)C(O)=O)=CN2N=C1NCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 YASUXVMOGKNGSN-UHFFFAOYSA-N 0.000 description 1
- DWWQHIBEFOFHSG-UHFFFAOYSA-N 2-[6-[3-(4-benzhydryloxypiperidin-1-yl)propylamino]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropan-1-ol Chemical compound C1=CC2=NC(C(C)(CO)C)=CN2N=C1NCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 DWWQHIBEFOFHSG-UHFFFAOYSA-N 0.000 description 1
- BCXQGWZGYZZHES-UHFFFAOYSA-N 2-[6-[3-(4-benzhydryloxypiperidin-1-yl)propylamino]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanamide;dihydrochloride Chemical compound Cl.Cl.C1=CC2=NC(C(C)(C(N)=O)C)=CN2N=C1NCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 BCXQGWZGYZZHES-UHFFFAOYSA-N 0.000 description 1
- YMJMGMABXHSGAM-UHFFFAOYSA-N 2-[6-[3-(4-benzhydryloxypiperidin-1-yl)propylamino]imidazo[1,2-b]pyridazin-2-yl]-n,n,2-trimethylpropanamide;dihydrochloride Chemical compound Cl.Cl.C1=CC2=NC(C(C)(C)C(=O)N(C)C)=CN2N=C1NCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 YMJMGMABXHSGAM-UHFFFAOYSA-N 0.000 description 1
- FUZDTXXOJNDAGN-UHFFFAOYSA-N 2-[6-[3-(4-benzhydrylpiperazin-1-yl)propyl]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoic acid Chemical compound C1=CC2=NC(C(C)(C(O)=O)C)=CN2N=C1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 FUZDTXXOJNDAGN-UHFFFAOYSA-N 0.000 description 1
- AIUCIGDKSCUAKY-UHFFFAOYSA-N 2-[6-[4-(4-benzhydryloxypiperidin-1-yl)butylamino]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoic acid Chemical compound C1=CC2=NC(C(C)(C(O)=O)C)=CN2N=C1NCCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 AIUCIGDKSCUAKY-UHFFFAOYSA-N 0.000 description 1
- XIDWGTFDBMALGG-UHFFFAOYSA-N 2-[tert-butyl(diphenyl)silyl]oxyethanol Chemical compound C=1C=CC=CC=1[Si](OCCO)(C(C)(C)C)C1=CC=CC=C1 XIDWGTFDBMALGG-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- 125000006016 2-bromoethoxy group Chemical group 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- HTKXERVWYLCGDU-UHFFFAOYSA-N 3-[tert-butyl(diphenyl)silyl]oxypropyl 4-benzhydryloxypiperidine-1-carboxylate Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCCCOC(=O)N(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 HTKXERVWYLCGDU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- GLIYWCMRDHLCGT-UHFFFAOYSA-N 6-(3-chloropropylsulfanyl)-7-propan-2-yl-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(SCCCCl)C(C(C)C)=CC2=NC=NN21 GLIYWCMRDHLCGT-UHFFFAOYSA-N 0.000 description 1
- BFDVLRLJMIXPIU-UHFFFAOYSA-N 6-(4-benzhydryloxypiperidin-1-yl)-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound C1CN(C2=NN3N=CN=C3C=C2)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 BFDVLRLJMIXPIU-UHFFFAOYSA-N 0.000 description 1
- CNNQAVCAAWOESC-UHFFFAOYSA-N 6-(6-bromohexylsulfanyl)-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(SCCCCCCBr)C(C)=CC2=NC=NN21 CNNQAVCAAWOESC-UHFFFAOYSA-N 0.000 description 1
- FMZLZRIOSLTNHQ-UHFFFAOYSA-N 6-[2-(2-bromoethoxy)ethylsulfanyl]-7-tert-butyl-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(SCCOCCBr)C(C(C)(C)C)=CC2=NC=NN21 FMZLZRIOSLTNHQ-UHFFFAOYSA-N 0.000 description 1
- XINLHXFZMJAUCF-UHFFFAOYSA-N 6-[2-[2-(4-benzhydryloxypiperidin-1-yl)ethoxy]ethoxy]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound CC1=CC2=NC=NN2N=C1OCCOCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 XINLHXFZMJAUCF-UHFFFAOYSA-N 0.000 description 1
- HPESCMYFIFJBAT-WLHGVMLRSA-N 6-[2-[2-(4-benzhydryloxypiperidin-1-yl)ethoxy]ethylsulfanyl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CC1=CC2=NC=NN2N=C1SCCOCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 HPESCMYFIFJBAT-WLHGVMLRSA-N 0.000 description 1
- HDPVWBZQPSHBLL-WLHGVMLRSA-N 6-[2-[2-(4-benzhydryloxypiperidin-1-yl)ethoxy]ethylsulfanyl]-[1,2,4]triazolo[1,5-b]pyridazine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC2=NC=NN2N=C1SCCOCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 HDPVWBZQPSHBLL-WLHGVMLRSA-N 0.000 description 1
- FUJOBGXYLMCGJH-UHFFFAOYSA-N 6-[2-[2-(4-benzhydrylpiperazin-1-yl)ethoxy]ethylsulfanyl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine;dihydrochloride Chemical compound Cl.Cl.CC1=CC2=NC=NN2N=C1SCCOCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 FUJOBGXYLMCGJH-UHFFFAOYSA-N 0.000 description 1
- SXSONUVTSNJBCS-UHFFFAOYSA-N 6-[3-(4-benzhydryloxypiperidin-1-yl)propoxy]-2-phenyl-[1,2,4]triazolo[1,5-b]pyridazine;hydrochloride Chemical compound Cl.C1CC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1CCCOC(=NN1N=2)C=CC1=NC=2C1=CC=CC=C1 SXSONUVTSNJBCS-UHFFFAOYSA-N 0.000 description 1
- LSRXESIJVQPMRZ-WLHGVMLRSA-N 6-[3-(4-benzhydryloxypiperidin-1-yl)propoxy]-7-propan-2-yl-[1,2,4]triazolo[1,5-b]pyridazine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CC(C)C1=CC2=NC=NN2N=C1OCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LSRXESIJVQPMRZ-WLHGVMLRSA-N 0.000 description 1
- PHWDDVURLZYZLM-WLHGVMLRSA-N 6-[3-(4-benzhydryloxypiperidin-1-yl)propoxy]imidazo[1,2-b]pyridazine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC2=NC=CN2N=C1OCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 PHWDDVURLZYZLM-WLHGVMLRSA-N 0.000 description 1
- PGFUOOYLLXKANO-UHFFFAOYSA-N 6-[3-(4-benzhydryloxypiperidin-1-yl)propylamino]-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(O)=O)=C(C)N=C2C=CC=1NCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 PGFUOOYLLXKANO-UHFFFAOYSA-N 0.000 description 1
- GABWPJXNNIJZNR-UHFFFAOYSA-N 6-[3-(4-benzhydryloxypiperidin-1-yl)propylamino]imidazo[1,2-b]pyridazine-2-carboxylic acid Chemical compound C1=CC2=NC(C(=O)O)=CN2N=C1NCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 GABWPJXNNIJZNR-UHFFFAOYSA-N 0.000 description 1
- LQXWLXLJAQZZTR-WLHGVMLRSA-N 6-[6-(4-benzhydryloxypiperidin-1-yl)hexylsulfanyl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CC1=CC2=NC=NN2N=C1SCCCCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LQXWLXLJAQZZTR-WLHGVMLRSA-N 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- DLVXWWWYCKTUBV-UHFFFAOYSA-N 6-chloro-2-methoxyimidazo[1,2-b]pyridazine Chemical compound N1=C(Cl)C=CC2=NC(OC)=CN21 DLVXWWWYCKTUBV-UHFFFAOYSA-N 0.000 description 1
- SPPCXCJWUYLSNX-UHFFFAOYSA-N 6-chloro-2-methyl-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound C1=CC(Cl)=NN2N=C(C)N=C21 SPPCXCJWUYLSNX-UHFFFAOYSA-N 0.000 description 1
- QPUBOGNHAFQPOP-UHFFFAOYSA-N 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound C1=CC(Cl)=NN2C(C(O)=O)=C(C)N=C21 QPUBOGNHAFQPOP-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- PSXSNFIFCCVXII-UHFFFAOYSA-N 7-tert-butyl-6-chloro-[1,2,4]triazolo[1,5-b]pyridazine Chemical compound N1=C(Cl)C(C(C)(C)C)=CC2=NC=NN21 PSXSNFIFCCVXII-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- YCZLHUWOQLNUSM-UHFFFAOYSA-N CC(C)(C1=CN2C(=N1)C=CC(=N2)CCCCCl)C(=O)O Chemical compound CC(C)(C1=CN2C(=N1)C=CC(=N2)CCCCCl)C(=O)O YCZLHUWOQLNUSM-UHFFFAOYSA-N 0.000 description 1
- GUHNXZHEGOTUGT-UHFFFAOYSA-N CC(C)(C1=CN2C(=N1)C=CC(=N2)CCCO)C(=O)O Chemical compound CC(C)(C1=CN2C(=N1)C=CC(=N2)CCCO)C(=O)O GUHNXZHEGOTUGT-UHFFFAOYSA-N 0.000 description 1
- DHTOUDZFAPPEBQ-UHFFFAOYSA-N CC(C)(C1=CN2C(=N1)C=CC(=N2)CCCOS(=O)(=O)C)C(=O)O Chemical compound CC(C)(C1=CN2C(=N1)C=CC(=N2)CCCOS(=O)(=O)C)C(=O)O DHTOUDZFAPPEBQ-UHFFFAOYSA-N 0.000 description 1
- DWMKPMGFERFSKA-UHFFFAOYSA-N CC1=CC2=NC(=CN2N=C1Cl)C(C)(C)C(=O)O Chemical compound CC1=CC2=NC(=CN2N=C1Cl)C(C)(C)C(=O)O DWMKPMGFERFSKA-UHFFFAOYSA-N 0.000 description 1
- NAJWJEPLQFCUNR-UHFFFAOYSA-N CCC(=O)OCC(C)C1=CN2C(=N1)C=CC(=N2)Cl Chemical compound CCC(=O)OCC(C)C1=CN2C(=N1)C=CC(=N2)Cl NAJWJEPLQFCUNR-UHFFFAOYSA-N 0.000 description 1
- ODDOSXXHWBIJMB-UHFFFAOYSA-N CCC(C)(C1=CN2C(=N1)C=CC(=N2)Cl)C(=O)O Chemical compound CCC(C)(C1=CN2C(=N1)C=CC(=N2)Cl)C(=O)O ODDOSXXHWBIJMB-UHFFFAOYSA-N 0.000 description 1
- YXCOOISILQMMIO-UHFFFAOYSA-N CCC(CC(CC)C(=O)O)C1=CN2C(=N1)C=CC(=N2)Cl Chemical compound CCC(CC(CC)C(=O)O)C1=CN2C(=N1)C=CC(=N2)Cl YXCOOISILQMMIO-UHFFFAOYSA-N 0.000 description 1
- JKMXQKJZRILLHQ-UHFFFAOYSA-N CCl.I Chemical compound CCl.I JKMXQKJZRILLHQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108700000434 Cannabis sativa edestin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229940105129 Chemotaxis inhibitor Drugs 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- JQZMCGDRCKZXER-UHFFFAOYSA-N Cl.Cl.Cl.CCC(O)=O Chemical compound Cl.Cl.Cl.CCC(O)=O JQZMCGDRCKZXER-UHFFFAOYSA-N 0.000 description 1
- YVDNDIRAYCRCOJ-UHFFFAOYSA-N Cl.N=1C=NN2N=CC=CC21 Chemical compound Cl.N=1C=NN2N=CC=CC21 YVDNDIRAYCRCOJ-UHFFFAOYSA-N 0.000 description 1
- CDISZIFOXPMDNW-UHFFFAOYSA-N ClCCCC(CC)SC=1C(=CC=2N(N1)N=CN2)C(C)C Chemical compound ClCCCC(CC)SC=1C(=CC=2N(N1)N=CN2)C(C)C CDISZIFOXPMDNW-UHFFFAOYSA-N 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical group FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- ATWLCPHWYPSRBQ-UHFFFAOYSA-N N-Methylacetoacetamide Chemical compound CNC(=O)CC(C)=O ATWLCPHWYPSRBQ-UHFFFAOYSA-N 0.000 description 1
- LSCNSSNMXYCFSX-UHFFFAOYSA-N NC(C(CN(CC1)CCC1OC(C1=CC=CC=C1)C1=CC=CC=C1)O)(N)N Chemical compound NC(C(CN(CC1)CCC1OC(C1=CC=CC=C1)C1=CC=CC=C1)O)(N)N LSCNSSNMXYCFSX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- CYKIHIBNSFRKQP-UHFFFAOYSA-N benzo[f][1]benzothiole Chemical compound C1=CC=C2C=C(SC=C3)C3=CC2=C1 CYKIHIBNSFRKQP-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002819 chemotaxis inhibitor Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- GGUGICKXGAYKDN-UHFFFAOYSA-N cyclopropanecarboxylic acid;dihydrochloride Chemical compound Cl.Cl.OC(=O)C1CC1 GGUGICKXGAYKDN-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- OCZUWDQSMLAHBV-UHFFFAOYSA-N ethyl 2-(3,6-dichloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropanoate Chemical compound C1=CC(Cl)=NN2C(Cl)=C(C(C)(C)C(=O)OCC)N=C21 OCZUWDQSMLAHBV-UHFFFAOYSA-N 0.000 description 1
- RMQQYKZWLJTDIP-UHFFFAOYSA-N ethyl 2-(6-chloro-3-methylimidazo[1,2-b]pyridazin-2-yl)-2-methylpropanoate Chemical compound C1=CC(Cl)=NN2C(C)=C(C(C)(C)C(=O)OCC)N=C21 RMQQYKZWLJTDIP-UHFFFAOYSA-N 0.000 description 1
- CLDRHXVMIBHJDT-UHFFFAOYSA-N ethyl 2-[6-(3-hydroxypropyl)imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoate Chemical compound N1=C(CCCO)C=CC2=NC(C(C)(C)C(=O)OCC)=CN21 CLDRHXVMIBHJDT-UHFFFAOYSA-N 0.000 description 1
- JKWMSPCECYIVSG-UHFFFAOYSA-N ethyl 2-[6-(4-chlorobutyl)imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoate Chemical compound N1=C(CCCCCl)C=CC2=NC(C(C)(C)C(=O)OCC)=CN21 JKWMSPCECYIVSG-UHFFFAOYSA-N 0.000 description 1
- WLEBOGWUIPJLQP-UHFFFAOYSA-N ethyl 2-[6-[3-(4-benzhydryloxypiperidin-1-yl)propyl]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoate Chemical compound C1=CC2=NC(C(C)(C)C(=O)OCC)=CN2N=C1CCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 WLEBOGWUIPJLQP-UHFFFAOYSA-N 0.000 description 1
- BUQSILYXUFJKFU-UHFFFAOYSA-N ethyl 2-[6-[4-(4-benzhydryloxypiperidin-1-yl)butyl]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoate Chemical compound C1=CC2=NC(C(C)(C)C(=O)OCC)=CN2N=C1CCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 BUQSILYXUFJKFU-UHFFFAOYSA-N 0.000 description 1
- RTGBDUHHMVGYSB-UHFFFAOYSA-N ethyl 2-[6-[4-(4-benzhydryloxypiperidin-1-yl)butyl]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoate;dihydrochloride Chemical compound Cl.Cl.C1=CC2=NC(C(C)(C)C(=O)OCC)=CN2N=C1CCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 RTGBDUHHMVGYSB-UHFFFAOYSA-N 0.000 description 1
- GZQXCEBOAXHBTF-UHFFFAOYSA-N ethyl 2-aminoacetate;dihydrochloride Chemical compound Cl.Cl.CCOC(=O)CN GZQXCEBOAXHBTF-UHFFFAOYSA-N 0.000 description 1
- RJXFYTUBGWZSRP-UHFFFAOYSA-N ethyl 2-methyl-2-[6-(3-methylsulfonyloxypropyl)imidazo[1,2-b]pyridazin-2-yl]propanoate Chemical compound N1=C(CCCOS(C)(=O)=O)C=CC2=NC(C(C)(C)C(=O)OCC)=CN21 RJXFYTUBGWZSRP-UHFFFAOYSA-N 0.000 description 1
- HCRBXQFHJMCTLF-UHFFFAOYSA-N ethyl 2-methylbutyrate Chemical compound CCOC(=O)C(C)CC HCRBXQFHJMCTLF-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- NBEMQPLNBYYUAZ-UHFFFAOYSA-N ethyl acetate;propan-2-one Chemical compound CC(C)=O.CCOC(C)=O NBEMQPLNBYYUAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- WDAXFOBOLVPGLV-UHFFFAOYSA-N ethyl isobutyrate Chemical compound CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002483 hydrogen compounds Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical group N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- CRBLYSJMKZONET-UHFFFAOYSA-N n-[3-(4-benzhydryloxypiperidin-1-yl)propyl]-2-phenyl-[1,2,4]triazolo[1,5-b]pyridazin-6-amine Chemical compound C1CC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1CCCNC(=NN1N=2)C=CC1=NC=2C1=CC=CC=C1 CRBLYSJMKZONET-UHFFFAOYSA-N 0.000 description 1
- SAHIUTLSCCDMPA-WLHGVMLRSA-N n-[3-(4-benzhydryloxypiperidin-1-yl)propyl]-2-tert-butyl-[1,2,4]triazolo[1,5-b]pyridazin-6-amine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.N=1N2N=C(C(C)(C)C)N=C2C=CC=1NCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 SAHIUTLSCCDMPA-WLHGVMLRSA-N 0.000 description 1
- GPFXNLYPDHXNQT-UHFFFAOYSA-N n-[4-(4-benzhydryloxypiperidin-1-yl)butyl]-[1,2,4]triazolo[1,5-b]pyridazin-6-amine Chemical compound C1=CC2=NC=NN2N=C1NCCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 GPFXNLYPDHXNQT-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- UZGLIIJVICEWHF-UHFFFAOYSA-N octogen Chemical group [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 UZGLIIJVICEWHF-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
- 229960000247 phenylmercuric borate Drugs 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- LMRCKXYHPYNEJV-UHFFFAOYSA-N piperazine;piperidine Chemical class C1CCNCC1.C1CNCCN1 LMRCKXYHPYNEJV-UHFFFAOYSA-N 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- WGDNDOWOHURNOT-UHFFFAOYSA-N propan-2-yl 2-(6-chloro-7-methylimidazo[1,2-b]pyridazin-2-yl)-2-methylpropanoate Chemical compound N1=C(Cl)C(C)=CC2=NC(C(C)(C)C(=O)OC(C)C)=CN21 WGDNDOWOHURNOT-UHFFFAOYSA-N 0.000 description 1
- QPYHWTXWAZJVDT-UHFFFAOYSA-N propan-2-yl 2-[6-(2-hydroxyethylamino)imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoate Chemical compound N1=C(NCCO)C=CC2=NC(C(C)(C)C(=O)OC(C)C)=CN21 QPYHWTXWAZJVDT-UHFFFAOYSA-N 0.000 description 1
- FXSZGKYGUFCBQY-UHFFFAOYSA-N propanoic acid;dihydrochloride Chemical compound Cl.Cl.CCC(O)=O FXSZGKYGUFCBQY-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- WFJZBOIOPMOUCB-UHFFFAOYSA-N pyridazine;hydrochloride Chemical compound Cl.C1=CC=NN=C1 WFJZBOIOPMOUCB-UHFFFAOYSA-N 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960003090 seratrodast Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- INPKIYXYNUEFEG-UHFFFAOYSA-N tert-butyl 2-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropanoate Chemical compound N1=C(Cl)C=CC2=NC(C(C)(C)C(=O)OC(C)(C)C)=CN21 INPKIYXYNUEFEG-UHFFFAOYSA-N 0.000 description 1
- YXUWXSYFSWJHID-UHFFFAOYSA-N tert-butyl 2-[6-[3-(4-benzhydryloxypiperidin-1-yl)propoxy]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropanoate Chemical compound C1=CC2=NC(C(C)(C)C(=O)OC(C)(C)C)=CN2N=C1OCCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 YXUWXSYFSWJHID-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- HLIDDDMWPWGYSH-UHFFFAOYSA-N triazolo[1,5-b]pyridazine Chemical compound N1=CC=CC2=CN=NN21 HLIDDDMWPWGYSH-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a nasal preparation useful as a prophylactic / therapeutic agent for allergic rhinitis and the like.
- a r 1 and A r 2 is shows also an aromatic group optionally having a substituent, A r 1 and A r 2 is to form a condensed ring group together with the adjacent carbon atoms
- Ring B represents a nitrogen-containing heterocyclic ring which may have a substituent, and X and Y are the same or different and each represents a bond, an oxygen atom, S (O) p (p is an integer of 0 to 2) ), NR 4 (R 4 represents a hydrogen atom or a lower alkyl group) or a divalent linear lower carbon atom which may have a substituent and may be via 1 to 3 hetero atoms.
- A represents a hydrogen group
- A represents a nitrogen atom or CR 7
- R 7 represents a hydrogen atom, a halogen atom, a hydrocarbon group which may have a substituent, an acyl group or a hydroxy group which may have a substituent. indicates shown
- RR 2 and R 3 are the same or different and each is a hydrogen atom, a halogen atom, substituted It may also be a hydrocarbon group, a hydroxy group optionally having a Ashiru groups or substituents
- R 8 denotes a water atom, lower alkyl optionally substituted by hydroxy group or Karupoki sill group.
- a salt thereof is an antihistamine and / or an eosinophil chemotaxis inhibitor, an antiallergic agent, asthma, allergic conjunctivitis, allergic rhinitis, chronic juvenile measles or atopic dermatitis Prevention and treatment
- dosage forms include tablets (including sugar-coated tablets and film-coated tablets), pills, capsules (including microcapsules), granules, fine granules, powders, syrups, emulsions, Suspensions, injections, inhalants, and ointments are disclosed.
- a r 1 and A r 2 is shows also an aromatic group optionally having a substituent, A r 1 and A r 2 is to form a condensed ring group together with the adjacent carbon atoms
- Ring B represents a nitrogen-containing heterocyclic ring which may have a substituent, and X and Y are the same or different and each represents a bond, an oxygen atom, S ( ⁇ ) p (p is an integer of 0 to 2) ), NR 4 (R 4 represents a hydrogen atom or a lower alkyl group) or a divalent linear lower carbonized group which may have a substituent and may be via 1 to 3 hetero atoms.
- A represents a hydrogen atom
- A represents a nitrogen atom or CR 7
- R 7 represents a hydrogen atom, a halogen atom, a hydrocarbon group which may have a substituent, an acyl group or a hydroxy group which may have a substituent
- R 1 R 2 and R 3 are the same or different and each have a hydrogen atom, a halogen atom
- R 8 represents a hydrogen atom, a hydroxy group or a carboxyl group which may be substituted by a hydrogen atom or a lower alkyl group.
- the nitrogen-containing heterocyclic ring represented by the ring B is represented by the formula
- n 0 or 1
- the use of a compound represented by the formula (I) or a salt thereof or a prodrug thereof as a nasal drop can unexpectedly and effectively exert an excellent therapeutic effect on allergic rhinitis. I found it. The present inventors have further studied based on these findings, and as a result, completed the present invention.
- a r 1 and A r 2 is shows also an aromatic group optionally having a substituent, A r 1 and A r 2 is to form a condensed ring group together with the adjacent carbon atoms
- Ring B represents a nitrogen-containing heterocyclic ring which may have a substituent, and X and Y are the same or different and each represents a bond, an oxygen atom, S (O) p (p is an integer of 0 to 2) ), NR 4 (R 4 represents a hydrogen atom or a lower alkyl group) or a divalent linear lower carbon atom which may have a substituent and may be via 1 to 3 hetero atoms.
- A represents a hydrogen group
- A represents a nitrogen atom or CR 7
- R 7 represents a hydrogen atom, a halogen atom, a hydrocarbon group which may have a substituent, an acyl group or a hydroxy group which may have a substituent. indicates shown
- RR 2 and R 3 are the same or different and each is a hydrogen atom, a halogen atom, substituted It may also be a hydrocarbon group, a hydroxy group optionally having a Ashiru groups or substituents
- R 8 denotes a water atom, lower alkyl optionally substituted by hydroxy group or Karupoki sill group.
- the nitrogen-containing heterocyclic ring represented by the ring B is represented by the formula
- a nasal drop comprising a compound represented by the formula or a salt thereof or a prodrug thereof;
- Ar ′ and Ar 2 each represent an aromatic group which may have a substituent, and Ar 1 and Ar 2 together with adjacent carbon atoms form a condensed ring group.
- Ring B represents a nitrogen-containing heterocyclic ring which may have a substituent, and X and Y are the same or different and each represents a bond, an oxygen atom, S ( ⁇ ) p (p is an integer of 0 to 2) ), NR 4 (R 4 represents a hydrogen atom or a lower alkyl group) or a divalent linear lower carbonized group which may have a substituent and may be via 1 to 3 hetero atoms.
- A represents a hydrogen group
- A represents a nitrogen atom or CR 7
- R 7 represents a hydrogen atom, an octogen atom, a hydrocarbon group which may have a substituent, an acyl group or a hydroxy group which may have a substituent
- RR 2 and R 3 are the same
- R 8 is a hydrogen atom or a lower alkyl group. It represents a hydroxy group or a carboxyl group which may be substituted.
- the nitrogen-containing heterocyclic ring represented by the ring B is represented by the formula
- a method for preventing and treating allergic rhinitis comprising administering an effective amount of a nasal drop containing the compound represented by the formula (I) or a salt thereof or a prodrug thereof; and
- a r 1 and A r 2 is shows also an aromatic group optionally having a substituent, A r 1 and A r 2 is to form a condensed ring group together with the adjacent carbon atoms
- Ring B represents a nitrogen-containing heterocyclic ring which may have a substituent, and X and Y are the same or different and each represents a bond, an oxygen atom, S ( ⁇ ) p (p is an integer of 0 to 2) ), NR 4 (R 4 represents a hydrogen atom or a lower alkyl group) or a divalent linear lower carbon atom which may have a substituent and may be via 1 to 3 hetero atoms.
- A represents a hydrogen group
- A represents a nitrogen atom or CR 7
- R 7 represents a hydrogen atom, a halogen atom, a hydrocarbon group which may have a substituent, an acyl group or a hydroxy group which may have a substituent
- R ′, R 2 and R 3 are the same or different and each have a hydrogen atom, a halogen atom, or a substituent
- R 8 represents a hydrocarbon group which may be substituted, an acyl group or a hydroxy group which may have a substituent
- R 8 represents a hydroxy group or a carboxy group which may be substituted with a hydrogen atom, a lower alkyl group.
- the nitrogen-containing heterocyclic ring represented by the ring B is represented by the formula
- Ar 1 and Ar 2 are (i) a halogen atom, (ii) C, 6 alkylenedioxy, (iii) nitro, (iv) cyano, (V) optionally halogenated C, — 6 alkyl, (vi) an optionally halogenated C 2 - 6 alkenyl, (vi i) halogenation which may be C 2 6 alkynyl, (vi ii) C 3 - 6 cycloalkyl, (ix) 1 3 to 3 halogen atoms, mono- or di-C 6 alkylamino or d-6 alkoxy-d-6 alkoxy optionally having a carbonyl compound, (X) optionally halogenated C i - 6 alkylthio, (xi) hydroxy, (xii) amino, (xiii) mono- d-6 Arukiruamino, (xiv) di - C, 6 Arukirua amino, (XV) 5 or 6
- R 8 is a hydrogen atom, C, - 6 alkyl optionally substituted hydroxy group or force Rupokishiru group shown,] may form a fused ring group represented by,
- the ring B is composed of (i) a halogen atom, (ii) d-6 alkylenedioxy, (iii) a nitro mouth, (iv) cyano, (V) an optionally halogenated d- 6 alkyl, (vi) an optionally halogenated C 2 - 6 alkenyl, (vii) optionally halogenated and C 2 - 6 alkynyl, (viii) C 3 - 6 cycloalkyl, (ix) 1 to 3 halogen atoms, Mono- or di-C 6 -alkylamino or C 6 -alkoxy-C fi alkoxy optionally having carbonyl, (X) optionally halogenated d-6 alkylthio, (xi) hydroxy, (Xii)
- Ararukiruokishi and may be substituted with a group selected from the group consisting of (xxix) Okiso comprises one nitrogen atom as little further nitrogen atom, to 1 selected from oxygen atom and sulfur atom 3 Represents a 3- to 13-membered nitrogen-containing heterocyclic ring which may contain a hetero atom,
- X and Y are the same or different, respectively; (1) a bond, (2) an oxygen atom, (3) S (O) p (p is an integer of 0 to 2), 4 NR 4 (R 4 is a hydrogen atom or a straight chain. other denotes a branched d-s alkyl group) or 5 (i) a halogen atom, (ii) C i 6 alkylene O carboxymethyl, (iii) nitro, (iv) Shiano, is (V) halide which may be C - 6 alkyl, (vi) an optionally halogenated C 2 one 6 alkenyl, (vii) optionally halogenated optionally C 2 - 6 alkynyl, (viii) C 3 - 6 cycloalkyl, (Ix) 1 to 3 halogen atoms, mono- or di-
- Ariru Ichiriki Rubamoiru (xxiv) sulfo, (xxv) C alkylsulfonyl, (xxvi) C 6,.
- Ariru Okishi, (xxviii) C 7 _ 16 7 Rarukiruokishi and (xxix) may have a substituent group selected from the group consisting of Okiso, heteroatoms to 1 Ru is selected from oxygen atom and a sulfur atom to three of linear may also be divalent to have through - 6 represents a hydrocarbon group,
- A is a nitrogen atom or CR 7
- R 7 is (1) hydrogen atom, (2) a halogen atom, (3) (i) a halogen atom, (ii) d 6 alkylene O carboxymethyl, (iii) nitro, (iv) Cyano, (V) optionally halogenated C, 6 alkyl, (vi) optionally halogenated C 26 alkenyl, (vii) optionally halogenated C 26 alkynyl, ( viii) C 3 - 6 cycloalkyl, (ix) 1 to 3 C androgenic atoms, mono - or di d-6 alkylamino or d-6 alkoxy
- (X) may be halogenated — 6- alkylthio, (xi) hydroxy, (xii) amino, (xiii) mono C, 6- alkylamino, (xiv ) Gee d-6 Arukiruamino, (XV) 5 or 6 membered cyclic Amino, (xvi) C, - 6 alkyl - carbonyl, (xvii) Karupokishi Le, (xviii) C i-6 alkoxy - power Ruponiru, (xix) Lumbamoyl, (xx) thiocarbamoyl, (xxi) mono-alkyl-lumbamoyl, (xxii) di-C, 6- alkyl-lumbamoyl, (xxiii) Ce !.
- R 9 is (a) hydrogen atom, (b) (i) halogen atom, (ii) ⁇ 6 alkylenedioxy, (iii) nitro, (iv) Shiano, (V) optionally C 6 alkyl which may be halogenated, (vi) optionally C 2 may be halogenated - 6 alkenyl, (vii) optionally C 2 6 may be halogenated alkynyl, (viii) C 3 6 cycloalkyl,
- (X) may be halogenated d-6 alkylthio, (xi) hydroxy, (xii) Amino, (xiii) mono- d-6 Arukiruamino, (xiv) di - d 6 Arukirua Mino, to (XV) 5 to 6 Membered cyclic amino, (xvi) d-ealkyl-caprolucyl, (xvii) carboxyl, (xviii) C-alkoxy-caproxyl, (xix) capable rubamoyl, (XX) thiocarbamoyl, (xxi) mono-d-6alkyl- power Luba moil, (xxii) di-C, 6 alkyl - power Rubamoiru, (xxiii) C 6,.
- R 11 is a hydrogen atom, or (i) eight androgenic atom, (ii) C I 6 alkylene O carboxymethyl, (iii) nitro, (iv) Xia Bruno, ( V) optionally halogenated to C 6 alkyl, (vi) optionally halogenated C 2 6 alkenyl optionally have, (vii) optionally halogenated and C 2 6 ⁇ Rukiniru, (viii) C 3 6 cycloalkyl, (ix) 1 to 3 halogen atom, mono- or di - C, - 6 alkylamino or C i - 6 alkoxy Ichiriki Lupo Optionally substituted with C, —6 alkoxy, (X) optionally halogenated
- Ariruokishi, (xxviii) C 7 - 16 Ararukiruokishi and (xxix) O may be substituted with a group selected from the group consisting of Kiso C, - 6 alkyl group, c 2 one 6 alkenyl group, C 2 _ 6 alkynyl group , C 3 - 6 cycloalkyl group, C 3 - 6 and 1 to cycloalkyl groups to three C, - 6 group and also a benzene ring optionally having alkoxy groups are condensed, C 6 - 14 7 aryl group or C 7 - 16 7 represents a group represented by aralkyl a group), R 1Q is Ashiru group Ru indicated by a hydrogen atom or a C alkyl group), or,
- R 12 is a hydrogen atom or (i) a halogen atom, (ii) 0: - 6 alkylene O carboxymethyl, (iii) nitro, () Shiano, be (V) halide Good C, — s alkyl, (vi) optionally halogenated C 2 — 6 alkenyl, (vi i) optionally halogenated C 2 — 6 alkynyl, (vi ii) C 3 — 6 Cycloalkyl, (ix) 1 to 3 halogen atoms, mono- or di-d- 6 alkylamino or C 6 alkoxy-C 6 alkoxy, optionally having alkoxy, (X) halogenated which may be C Bok 6 alkylthio, (xi) hydroxy, (xii) Amino, (xiii) mono one d-6 Arukiruamino, (xiv) di - d-6 Arukiruamino, (X) halogenated
- Ariru - Power Rubamoiru (Xxiv) sulfo, (xxv) d Lukylsulfonyl, (xxvi) C 6 —,. Ariru, (xxvii) C 6,. Ariruoki Shi, (xxviii) C 7 16 Ararukiruokishi and (xxix) optionally substituted with a group selected from the group consisting of Okiso C, - 6 alkyl group, C 2 - 6 alkenyl group, C 2 - 6 alkynyl group, C 3 - 6 cycloalkyl group, C 3 - 6 cycloalkyl group and 1 to 3 C, - 6 group and also a benzene ring optionally having alkoxy groups are condensed,
- RR 2 and R 3 are (1) a hydrogen atom, (2) a halogen atom,
- R 13 is (a) a hydrogen atom, (b) ( i) an halogen atom, (iod- 6 alkylenedioxy, (Hi) nitro, (iv) cyano, (V) optionally halogenated C, -6 alkyl, (vi) halogenated which may C 2 - 6 alkenyl, (vii) optionally halogenated and C 2 - 6 alkynyl, (viii) C 3 one 6 cycloalkyl, (ix) 1 to 3 halogen atoms, mono- or di C i may have 6 alkylamino or C 6 alkoxy monocarbonyl — 6 alkoxy, (X
- one 6 alkynyl group, C 3 - 6 cycloalkyl group, C 3 - 6 cycloalkyl group and one to three d - 6 group optionally the benzene ring is condensed has alkoxy groups, C 6 - 14 Ariru groups or C 7 - 16 Ararukiru group or,
- R 15 is a hydrogen atom, or (i) a halogen atom, (ii) C, 16 alkylenedioxy, (iii) nitro, (iv) cyano, (V) halogenated (Vi) optionally halogenated C 2 — 6 alkenyl, (vii) optionally halogenated C 2 _ 6 alkynyl, (viii) C 3 — 6 cycloalkyl (Ix) 1 to 3 halogen atoms, mono- or di-alkylamino or C i-6 alkoxy-carbonyl optionally having C
- Ariru - Power Rubamoiru (xxiv) sulfo, (xxv) C, - B ⁇ alkylsulfonyl, (xxvi) C 6 i. Ariru, Ji (xxvii) 6 - 1 () Ariruoki Shi, (xxvi ii) ⁇ 7 16 Ararukiruokishi and (xxix) optionally substituted with a group selected from the group consisting of Okiso C, - 6 alkyl group, C 2 - 6 alkenyl, C 2 _ 6 alkynyl, C 3 - and 6 cycloalkyl group and one to three C, -6 benzene ring which may have an alkoxy group - 6 cycloalkyl, C 3 A group condensed with
- a group represented by C 6 shows a 4 Ariru group or C 7 6 Ararukiru group
- R 14 represents a hydrogen atom or a d 6 alkyl group), or an acyl group represented by
- R 16 is a hydrogen atom or (i) a halogen atom,, (ii) -6 alkylene O carboxymethyl, (iii) nitro, (iv) Shiano may be (V) halide C, 6 alkyl, (vi) an optionally halogenated C 2 6 alkenyl Le, (vi i) halogenated which may be C 2 6 alkynyl, (vi ii) C 3 6 cyclo alkyl, (ix ) 1 to 3 halogen atoms, mono - or di C I 6 alkylamino or C, - 6 may have an alkoxy Ichiriki Ruponiru C 6 alkoxy, (X) a C alkylthio which may be halogenated , (xi) hydroxy, (xi i) Amino, (xi ii) mono- d-6 Arukiruamino, (xiv) di - d 6 Arukiruamino
- C 6 — represents an aryl group or a C 7 aralkyl group
- R 8 is a hydrogen atom, C, - 6 alkyl optionally substituted hydroxy group or force Rupokishiru first [1] This shows the base section, wherein the agent,
- Ar 1 and Ar 2 are each derived from (1) a phenyl group which may be substituted with a halogen atom or C ⁇ 6 alkyl, or (2) a nitrogen atom, a sulfur atom and an oxygen atom other than a carbon atom.
- Z represents a nitrogen atom or a methine group
- Z 1 and Z 2 each represent a linear group optionally substituted with a hydroxy group, an oxo group or a d-alkyl group.
- Ar 1 and Ar 2 are phenyl groups, and ring B is a group represented by the formula
- Z ′ represents a methine group
- Z and Z 2 ′ represent a methylene group or an ethylene group
- X is a bond or an oxygen atom
- Y is — (CH 2 ) p
- Alpha is CR 7 '' (R 7 ' ' represents a hydrogen atom or a C, - 6 indicates an alkyl group) with, R 1 (1) hydrogen atom, (2) power Rupokishiru or C, - s alkoxy Ichiriki optionally substituted C 6 alkyl group Ruponiru (especially isopropyl) or (3) d-6 alkoxy one local Poniru in substituted have a good C 6 alkyl optionally at even better force Rubamoi group, with R 2 is a hydrogen atom, with R 3 is a hydrogen atom, a [1], wherein R 8 is a hydrogen atom Agent (12) The agent according to (1), wherein
- a r 1 and A r 2 are each (1) a halogen atom or a C, - 6 may be substituted with Al Kill phenyl group or (2) a nitrogen atom in addition to carbon atoms, a sulfur atom and an oxygen atom
- the agent according to item (1) which is a 5- or 8-membered aromatic heterocyclic group containing 1 to 4 heteroatoms selected,
- Ring B is a formula
- Z is represents nitrogen atom or a methine group
- Z 'and Z 2 are each hydro alkoxy group, Okiso group or C, - fi alkyl group optionally substituted with a linear C, - 4 alkylene group
- Z 1 and Z 2 are each straight-chain C, - 2 a [1 5], wherein the agent is an alkylene group,
- Y 1 and Y 2 are the same or different and are each a bond, an oxygen atom, S ( ⁇ ) ⁇ ( ⁇ is an integer of 0 to 2), NR 4 (R 4 is a hydrogen atom or lower alkyl) Represents a group), a carbonyl group, a carbonyloxy group or a formula
- R (Wherein, R 5 and R 6 are hydroxy groups or C are the same or different, - 4 alkyl group shows a) a group represented by to m and n are 0, respectively an integer of 4 (where, The sum of m and n is 6 or less)], the agent according to item [1],
- RRR 3 and R 7 are the same or different, respectively (1) hydrogen atom, (2) a carboxyl group or a C, - 6 alkoxy Ichiriki Ruponiru optionally substituted C 6 alkyl group group, ( 3) (: ⁇ 6 alkoxy group, (4) d- 6 alkoxy monocarbonyl group or (5) alkoxyl group, the agent according to item [1], [22] R 1 is (1) hydrogen atom , (2) (i) carboxyl, (ii) d-6 alkoxy monopropenyl, (iii) hydroxy or (iv) monopotassium or di-d- 6 alkyl optionally having a labamoyl group.
- Substitute with selected group which may be C, - 6 alkyl group, (3) C 6 -, 4 Ariru group, (4) C, - 6 alkoxy group, (5) C 6 alkoxy one carbonyl group, (6) a carboxyl group, ( 7) carboxyl or C, - 6 alkoxy - optionally substituted with carbonyl C, - 6 alkyl to have unprotected force Rubamoiru group, or (8) C 6 alkoxy - optionally substituted with a force Ruponiru good C 3 -. 6 No. (1) a cycloalkyl group claim wherein the agent,
- R 2 is a hydrogen atom, C, - 6 alkyl group, agents of the [1], wherein a d-6 alkoxy one carbonyl group or a carboxyl group,
- R 7 is a hydrogen atom, 'a halogen atom, C, - 6 alkyl group, agents of the [1], wherein a d-6 alkoxy one carbonyl group or force Rupokishiru group,
- A is CR 7 '(R 7' is a hydrogen atom, a halogen atom, d-6 alkyl group, C, - 6 alkoxy - Power Ruponiru a group or a carboxyl group) at a first (1) section, wherein Agent,
- the compound is 2- [6- [3- [4-[(diphenylmethoxy) piperidino] propylamino] imidazo [12-b] pyridazine-2-yl] -ethyl 2-ethylpropionate or a salt thereof
- the agent according to (1) which is
- the compound is 2- [6- [3- [4- (diphenylmethoxy) piperidino] propylamino] imidazo [12-b] pyridazine-12-yl] -12-methylpropionic acid or a salt thereof.
- the agent according to (1) which is
- the compound is 2- [6-] [3- [4- [diphenylmethoxy] piperidino] propylamino] _3-methylimidazo [12_b] pyridazine-2-yl] (I) the agent according to item (1), which is ethyl 2-methylpropionate or a salt thereof; [34] the compound is 2- [6- [3- [4- (diphenylmethylamino) piperidino] propylamino] imidazo [1,2—b] pyridazine-12-yl] ethyl monoethyl propionate or a salt thereof according to item [1], wherein the compound [3-5] is 2 _ [6-[3-[ 4- (diphenylmethoxy) piperidino] propylamino] -3-methylimidazo [1,2_b] pyridazine-2-yl] 1-2-methylpropionic acid or a salt thereof according to item [1],
- the compound is 2- [6- [3- [4- (diphenylmethoxy) piperidino] propylamino] imidazo [1,2-b] pyridazine-2-yl] _2-methylethyl propionate Nicohaku Agent according to item (1), which is an acid salt; and
- the compound is 2_ [6- [3- [4-1- (diphenylmethoxy) piperidino] propylamino] imidazo [1,2-b] pyridazine-2-yl] ethyl 2-ethylpropionate
- the compound according to item [1] which is a salt, is provided with (in addition to) the compound (I) or a salt thereof, which contains an asymmetric carbon in the structure. And these compounds or salts thereof may be either hydrates or anhydrides.
- a r 1 and A r 2 is shows the "optionally substituted aromatic group", A r 1 and A r 2 is to form a condensed ring group together with the adjacent carbon atoms You may.
- the “aromatic group” represented by A r 1 and A r 2 includes, for example,
- Monocyclic or condensed polycyclic aromatic hydrocarbon groups more specifically, phenyl, Tolyl, xylyl, biphenyl, 1-naphthyl, 2-naphthyl, 2-indenyl, 1-anthryl, 2-anthryl, 9-anthryl, 1-phenanthryl, 2-phenanthryl, 3-phenanthryl, 4-phenanthryl or 9-phenyl 6 to 14 membered monocyclic, such as C 6 —l 4 7 reel group such as phenanthryl (preferably phenyl, tolyl, xylyl, biphenyl, 1-naphthyl or 2-naphthyl) Or a fused polycyclic aromatic hydrocarbon group,
- One or more (preferably one or two, more preferably one) of these rings is an aromatic ring (for example, the above-mentioned aromatic hydrocarbon) Group, preferably a benzene ring, etc.) and a ring formed by condensing with a 6- to 14-membered monocyclic or condensed polycyclic aromatic hydrocarbon group of the above 1 and a carbon atom of the above 2
- a monovalent group capable of removing an arbitrary hydrogen atom from a ring formed by condensing a condensed aromatic heterocyclic group is used.
- aromatic group of the “aromatic group optionally having substituent (s)” represented by Ar 1 and Ar 2 , for example, a phenyl group is preferable.
- the “substituent” of the aromatic group represented by A r 1 and A r 2 includes, for example, (i) a halogen atom (eg, fluorine, chlorine, bromine, iodine), (ii) a lower alkylenedioxy group (eg, Mechirenjiokishi, C such Echirenjiokishi, - like 3 ⁇ Rukirenjiokishi group), (iii) nitro group, (iv) Shiano group, (V) halogen of which may be a lower alkyl group, have been (vi) halogenated also good low-grade alkenyl group, (vi i) optionally halogenated substituted lower alkynyl group, (vi ii) lower cycloalkyl group (e.g., cyclopropyl, cyclobutyl, Shikuropen chill, C 3, such as cyclohexyl - 6 (Ix) a lower alkoxy group which may be substituted,
- Ariruokishi group such Nafuchiruokishi
- (xxvii i) ⁇ Rarukiruokishi group (e.g., C 7 such Benjiruokishi - such as 16 Ararukiruokishi group) and the like.
- halogenated lower alkyl group examples include, for example, a lower alkyl group (eg, methyl) which may have 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine).
- halogenated lower alkenyl group and “optionally halogenated lower alkynyl group” include, for example, 1 to 3 halogen atoms (for example, fluorine, chlorine, bromine, iodine)
- a lower alkenyl group which may have (for example, vinyl, propyl, isopropyl, 2-butene-1-yl, 4-pentene-1-yl, 5-hexene-1-yl) Le C, such as 2 - 6 an alkenyl group, etc.) and 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, which may lower alkynyl group optionally having iodine) (e.g., 2 _ butyne one 1 one I le, 4-pentyne one 1-I le, such as connexin one 1-I le to 5-C 2 - 6 ⁇ And the like.
- Examples of the “optionally substituted lower alkoxy group” include, for example, 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine), mono, or di-lower alkylamino group (eg, methylamino, Jimechiruamino, Echirua amino, such as mono- one or di- C Bok 6 alkylamino group such as Jimechiruamino) or lower alkoxy - carbonyl group (e.g., have a C like alkoxy Ichiriki Ruponiru group) such as methoxycarbonyl, Etoki aryloxycarbonyl good not a lower alkoxy group (e.g., methoxy, ethoxy, Purobokishi, Isopurobo xylene, n _ butoxy, isobutoxy, sec- butoxy, C I 6 alkoxy group such as a t er t-Bed Bok alkoxy) and the like.
- a lower alkylthio group optionally having 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine) (for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, d- 6 alkylthio groups such as sec-butylthio and tert-butylthio), and the like.
- halogen atoms eg, fluorine, chlorine, bromine, iodine
- Specific examples include methylthio, difluoromethylthio, trifluoromethylthio,
- R 8 is as defined above. And condensed ring groups represented by It is.
- a r 'and A r 2 which may have a substituent aromatic hydrocarbon group (e.g., C 6 - 1 4 aromatic hydrocarbon group) are preferred, location substituent A phenyl group which may have a is more preferable. More specifically, A r 1 and A r 2 each include (1) a phenyl group optionally substituted with a halogen atom or C 6 alkyl or (2) a nitrogen atom, a sulfur atom and A 5- to 8-membered aromatic heterocyclic group containing 1 to 4 heteroatoms selected from oxygen atoms is preferred.
- the ring B represents “a nitrogen-containing heterocyclic ring which may have a substituent”.
- the nitrogen-containing heterocyclic ring represented by ring B has the formula
- the “nitrogen-containing heterocycle” represented by ring B includes, for example, one nitrogen atom, and further includes, for example, one to three heteroatoms selected from a nitrogen atom, an oxygen atom, a sulfur atom, and the like.
- a 3- to 13-membered nitrogen-containing heterocycle may be used.
- Examples of the substituent of the nitrogen-containing heterocyclic ring represented by ring B include, for example, a ⁇ substituent '' of the ⁇ aromatic group which may have a substituent '' represented by Ar 1 and Ar 2 . other, An oxo group or the like is used.
- ring B Preferred specific examples of ring B include, for example,
- Z represents a nitrogen atom or a methine group
- Z 1 and Z 2 each represent a hydroxy group, an oxo group, or a linear d- 4 alkylene group which may be substituted with a C, 6 alkyl group. .
- And the like are used.
- the - The " ⁇ 6 alkyl group" for example, methyl, Echiru, propyl, I an isopropyl, butyl, isobutyl, sec- butyl, tert- butyl, pentyl, straight or branched C, such as cyclohexyl, - such as 6 alkyl group are used.
- linear d- 4 alkylene group is, for example, a linear C ⁇ 4 alkylene group represented by methylene, ethylene, propylene, and butylene.
- linear d-4 alkylene group optionally substituted with a hydroxy group, an oxo group or a d-6 alkyl group” represented by Z 1 and Z 2 an unsubstituted linear d 4 such alkylene groups are used, in particular, an unsubstituted straight chain C, - 2 alkylene groups are preferred.
- B ring More preferably, as the B ring, piperidine, piperazine and the like are used.
- X and Y are the same or different, respectively; 1 bond, 2 oxygen atom, S S ( ⁇ ) p (p is an integer of 0 to 2), 4 NR 4 (R 4 is a hydrogen atom or Represents a lower alkyl group.)
- Or 5 represents a divalent linear lower hydrocarbon group which may have a substituent (s) and may have 1 to 3 heteroatoms.
- the same or different carbon atoms of a lower (d-6) hydrocarbon may be used.
- divalent linear lower hydrocarbon group examples include:
- (i) 6 alkylene groups (for example, _CH 2 —,-(CH 2 ) 2- , one (CH 2 ) 3 —, one (CH 2 ) 4 —, one (CH 2 ) 5 —, one (CH 2 ) 6 — etc.),
- C 2 — 6 alkynylene group for example, _C 3 C_, — C ⁇ C— CH 2 —, — CH 2 — C ⁇ C— CH 2 —,-(CH 2 ) 2 — C ⁇ C-CH 2 —,-(CH 2 ) 2 -C3C- (CH 2 ) 2 —, — (CH 2 ) 3 —C 3 C—CH 2 — and the like are used.
- Examples of the “substituent” of the “divalent straight-chain lower hydrocarbon group optionally having 1 to 3 hetero atoms” represented by X and Y include, for example, the above Ar 1 and Ar 2
- an oxo group and the like are used, and a hydroxy group or an oxo group is particularly preferable.
- X is preferably a bond, an oxygen atom or NH, and particularly preferably a bond or an oxygen atom.
- Y is, for example,
- Y 1 and Y 2 are the same or different and each has a bond, an oxygen atom, S (0)
- R 5 and R 6 are the same or different and each represents a hydroxy group or a C, 4 alkyl group.
- m and ⁇ are each 0 to A group represented by an integer 4 (however, the sum of m and n is 6 or less)] is used.
- R 5 and R 6 "C, - 4 alkyl group” includes, for example, methyl, Echiru, propyl, isopropyl, butyl, isobutyl, sec- butyl, straight-chain or branched, such as tert- butyl C, 4 alkyl groups and the like are used.
- Y for example, a bond, - (CH 2) 2 -0 -, - (CH 2) 3-0 -, - (CH 2) 4 -0-, - (CH 2) 6 - 0 -,-(CH 2 ) 2 -NH-,-(CH 2 ) 3 -NH-,-(CH 2 ) 4 -NH-,-(CH 2 ) 3 -S-,-CH 2 -CH (OH) -CH 2-0-, - (CH 2) 2 -CO- NH-, -CH 2 -CO- NH -, -CO-0- (CH 2) 2 - 0 -, -CO - 0 - (CH 2 ) 3-0-, - (CH 2) 6-NH-, _ (CH 2) 6 - S -, - (CH 2) 2 - 0- (CH 2) 2 - 0-, - (CH 2) 2 - 0- (CH 2) 2 -, etc. S- are preferred.
- A is a nitrogen atom or CR 7 (R 7 is a hydrogen atom, a halogen atom, a hydrocarbon group which may have a substituent, an acyl group or a substituent Shows a hydroxy group. ).
- the “halogen atom” represented by R 7 includes fluorine, chlorine, bromine, and iodine.
- the “hydrocarbon group” represented by R 7 is, for example, a group obtained by removing one hydrogen atom from a hydrocarbon compound, and examples thereof include an alkyl group, an alkenyl group, an alkynyl group, and a cycloalkyl group. And a chain or cyclic hydrocarbon group such as an aryl group or an aralkyl group.
- a linear (linear or branched) or cyclic hydrocarbon group having 1 to 16 carbon atoms is preferable, and a) an alkyl group [preferably a lower alkyl group (eg, methyl, ethyl, Mouth pill, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and other d- 6 alkyl groups)],
- a lower alkyl group eg, methyl, ethyl, Mouth pill, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and other d- 6 alkyl groups
- an alkenyl group [preferably, a lower alkenyl group (e.g., vinyl, Ariru, isopropenyl, butenyl, isobutenyl, C 2, such as sec- butenyl - such as 6 alkenyl group)],
- a lower alkenyl group e.g., vinyl, Ariru, isopropenyl, butenyl, isobutenyl, C 2, such as sec- butenyl - such as 6 alkenyl group
- alkynyl group [preferably, lower alkynyl group (e.g., propargyl, Echiniru, heptynyl, c 2 such hexynyl to 1 - such as 6 alkynyl group)]
- a cycloalkyl group [preferably, lower cycloalkyl group ( For example, cyclopropyl, cyclobutyl, cyclopentyl, one to three lower alkoxy groups
- aryl groups e.g., phenyl, tolyl, xylyl, biphenyl, 1-naphthyl, 2_naphthyl, 2_indenyl, 1-anthryl, 2-anthryl, 9_anthryl, 1_phenanthryl, 2_phenanthryl, 3 Fuenanto Lil, such as 4 _ Fuenantoriru or 9 Fuenantoriru (: 6 - such as 1 4 Ariru group, preferably phenyl group),
- aralkyl groups [preferably lower aralkyl groups (for example, benzyl, phenethyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2- Fueniruechiru, 2 Jifueniruechiru, 1-phenylpropyl, 2-phenylene Rupuropiru, 3-phenylpropyl, 4 _ phenylbutyl, 5-like C 7 16 Ararukiru group such as phenylene point pen chill, more preferably downy Njiru group) Is preferred.
- lower aralkyl groups for example, benzyl, phenethyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2- Fueniruechiru, 2 Jifueniruechiru, 1-phenylpropyl, 2-phenylene Rupuropiru, 3-phenylpropyl, 4 _
- Examples of the “substituent” of the “hydrocarbon group” represented by R 7 include the “substituent” of the “optionally substituted aromatic group” represented by Ar 1 and Ar 2 above. Group, as well as an oxo group.
- R 9
- the “hydrocarbon group” represented by R 9 represents a group obtained by removing one hydrogen atom from a hydrocarbon compound, and examples thereof include an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, and an aryl group. And a chain (linear or branched) or cyclic hydrocarbon group such as a aralkyl group. Specific examples include the “hydrocarbon group” represented by R 7 above, among which a chain or cyclic hydrocarbon group having 1 to 16 carbon atoms is preferred. In particular, lower (d 6 ) Alkyl groups are preferred.
- Examples of the “substituent” which the “hydrocarbon group” represented by R 9 may have include, for example, the “optionally substituted aromatic” represented by the above Ar ′ and Ar 2 Group '' In addition to the above “substituents”, oxo groups and the like are used.
- Examples of the “optionally substituted hydroxy group” represented by R 9 include, for example, those similar to the “optionally substituted hydroxy group” represented by R 7 described below, and the like. Is used.
- Examples of the “hydroxy group optionally having a substituent” represented by R 7 include, for example, the above-mentioned “having a substituent group” in place of a hydrogen atom of (1) a hydroxy group or (2) a hydroxy group.
- a hydrogen radical or a (5) carboxyl group is particularly preferred, and particularly preferred is a hydrogen atom, a halogen atom, a d-6 alkyl group, a d-6 alkoxycarbonyl or a carboxyl group.
- A is preferably a nitrogen atom or CR 7 ′ (R 7 ′ represents a hydrogen atom, a halogen atom, a d- 6 alkyl group, a d 6 alkoxy-carbonyl group or a carboxyl group), among which a nitrogen atom, CH or C—CH 3 is preferred, and a nitrogen atom or CH is particularly preferred.
- R 1 , R 2 and R 3 may be the same or different and each may have a hydrogen atom, a halogen atom, a hydrocarbon group which may have a substituent, an acyl group or a substituent. Shows a hydroxy group. ).
- the “halogen atom” represented by R ′, R 2 and R 3 includes fluorine, chlorine, bromine and iodine.
- Examples of the “optionally substituted hydrocarbon group” represented by RR 2 and R 3 include the “optionally substituted hydrocarbon group” represented by R 7 above. Is used.
- Haldroxy group optionally having substituent (s) represented by RR 2 and R 3
- substituent (s) represented by RR 2 and R 3
- R 7 the “optionally substituted hydroxy group” represented by the above R 7 is used.
- RR 2 and R 3 are the same or different and are (1) a hydrogen atom, (2) a carboxyl group or a 6 alkyl group optionally substituted by C alkoxy-carbonyl, (3) a C, 6 alkoxy group, ( 4) C, 6 alkoxy Ichiriki Ruponiru group, (5) force Rupokishiru group or (6) C 6 - 14 7 aryl group (especially phenylene le) are preferred, (1) a hydrogen atom, (2) power Rupokishiru group or - 6 an alkoxy - optionally substituted with a force Ruponiru C, 6 alkyl group, (3) d 6 alkoxy group, (4) 6 alkoxy Ichiriki Ruponiru group or (5) force Rupokishiru group is more preferable.
- R 1 (1) a hydrogen atom
- (2)) Karupokishiru, (ii) C, 6 alkoxy - Power Ruponiru, (iii) hydroxy or (iv) mono- or di-C, - 6 have an alkyl be substituted with a group which may be selected from the group consisting of a good force Rubamoiru unprotected d 6 alkyl group, (3) C 6 14 Ariru group, (4) d- 6 alkoxy group, (5) d- 6 alkoxy - carboxymethyl group, (6) carboxyl group, (7) force Rupokishiru or CI- 6 alkoxy Ichiriki optionally substituted with Ruponiru C, - 6 may have an alkyl force Rubamoiru group, Or
- R 2 is also preferably a hydrogen atom, a d-6 alkyl group, a d-5 alkoxy-carbonyl group or a carbonyl group.
- R 3 is preferably a hydrogen atom.
- R. 8 is a hydrogen atom, may be substituted with a lower alkyl group hydro alkoxy group.
- the “lower alkyl group” of the “hydroxyl group optionally substituted by a lower alkyl group” represented by R 8 includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec— And C 6 alkyl groups such as butyl, tert-butyl, pentyl, and hexyl.
- R 8 is preferably a hydrogen atom or a hydroxy group, and particularly preferably a hydrogen atom.
- a r 1 and A r 2 are each (1) halogen atom or C, - 6 alkyl optionally phenyl group or optionally substituted with (2) a nitrogen atom in addition to carbon atoms A 5- to 8-membered aromatic heterocyclic group containing 1 to 4 heteroatoms selected from, a sulfur atom and an oxygen atom;
- Z represents a nitrogen atom or a methine group
- Z 1 and Z 2 represent a linear d- 4 alkylene group which may be substituted with a hydroxy group, an oxo group or a d-6 alkyl group, respectively.
- X is a bond, an oxygen atom or NH
- Y is
- A is a nitrogen atom Or CR 7 ′
- R 7 ′ represents a hydrogen atom, a halogen atom, an alkyl group, a d 6 alkoxyl carbonyl group or a carbonyl group
- R 1 is (1) a hydrogen atom, (2) ( i) carboxyl, (ii) C, 6 alkoxycarbonyl, (iii) hydroxy or (iv) monovalent or di-d-6 alkyl optionally substituted with a group selected from the group consisting of rubamoyl.
- 6 alkyl a has unprotected force Rubamoiru group or (8), d-6 alkoxy - substituted with force Ruponiru which may be C 3 - 6 cycloalkyl group, R 2 is a hydrogen atom, d 6 Al kill group, Preferred are compounds in which d-6 alkoxy is a monopropyl or propyloxy group, R 3 is a hydrogen atom, and R 8 is a hydrogen atom or a hydroxyl group.
- a r 1 and A r 2 are phenyl groups, and ring B has the formula
- Z ′ represents a methine group
- Z and Z 2 ′ represent a methylene group or an ethylene group (preferably an ethylene group)
- X is a bond, an oxygen atom or NH
- Y is a group represented by — (CH 2 ) p 1 NH- (p 1 is an integer of 1 to 6)
- A is CR 7 ′ ′ (R 7 '' represents a hydrogen atom or an alkyl group)
- R i is (1) hydrogen atom, (2) power Rupokishiru or C -! 6 alkoxy - optionally substituted with a carbonyl C
- the prodrug of the compound (I) or a salt thereof (hereinafter, abbreviated as the compound (I) of the present invention) can be prepared by reacting the compound (I) of the present invention by a reaction with an enzyme, gastric acid, or the like under in vivo physiological conditions.
- a compound which is enzymatically oxidized, reduced, hydrolyzed, etc. to be converted into the compound (I) of the present invention, and a gastric acid, etc., which is hydrolyzed, etc. to be converted into the compound (I) of the present invention It can be a compound.
- Examples of the prodrug of the compound (I) of the present invention include compounds in which the amino group of the compound (I) of the present invention is acylated, alkylated, and phosphorylated (eg, the amino group of the compound (I) of the present invention is Eicosanoylation, Araraelization, Pentylamino Methylation, (5-methyl-2-oxo-1, 3-dioxolen-4-yl) methoxycarponylation, tetrahydrofuranylation, pyrrolidylmethylation, bivaloyloxymethylation, tert-butylated compound, etc.); Compounds in which the hydroxyl group of the compound (I) of the present invention is acylated, alkylated, phosphorylated, and borated (eg, the hydroxyl group of the compound (I) of the present invention is acetylated, palmitoylated, propanoylated, pivaloylated, succin
- the prodrug of the compound (I) of the present invention can be prepared by using a physiological drug such as described in Hirokawa Shoten, 1990, “Development of Pharmaceuticals,” Vol. 7, Molecular Design, pp. 163 to 198. May change to the compound of the present invention under appropriate conditions.
- Q 1 As the leaving group represented by Q 1, for example sodium, Al force Li metal such as potassium is used. Q 1 may be a hydrogen atom. '
- the leaving group represented by Q 2 for example, a halogen atom (e.g., chlorine, a bromine, iodine, etc.), C s - i.
- a halogen atom e.g., chlorine, a bromine, iodine, etc.
- C s - i An arylsulfonyloxy group (eg, benzenesulfonyloxy, p-tolylsulfonyloxy, etc.), a d-4 alkyl-sulfonyloxy group (eg, methanesulfonyloxy, etc.) and the like are used.
- the compound ( ⁇ ′ ′) or a salt thereof is generally used in an amount of about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of the compound ( ⁇ ⁇ ) or a salt thereof.
- This reaction is usually carried out in the presence of a base.
- a base examples include alkali metal hydrides such as sodium hydride and potassium hydride, alkali metal alkoxides such as sodium methoxide and sodium ethoxide. .
- reaction is carried out in alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, nitriles such as acetonitrile, ⁇ , ⁇ -dimethylformamide,
- alcohols such as methanol and ethanol
- ethers such as dioxane and tetrahydrofuran
- aromatic hydrocarbons such as benzene, toluene and xylene
- nitriles such as acetonitrile
- ⁇ , ⁇ -dimethylformamide The reaction can also be carried out in an inert solvent such as amides such as ⁇ , ⁇ -dimethylacetamide and sulfoxides such as dimethyl sulfoxide.
- the reaction temperature is usually about 10 to about 20 °, preferably about 50 to about 10 °.
- reaction time is generally about 30 minutes to about 24 hours, preferably about 1 to about 6 hours.
- Compound (I) or a salt thereof is
- the compound (IV) or a salt thereof is used usually in an amount of about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of the compound ( ⁇ ) or a salt thereof.
- This reaction is usually carried out in the presence of a base.
- the base include alkali metal hydrides such as sodium hydride and potassium hydride, and alkali metal hydrides such as sodium methoxide and sodium methoxide.
- Alkoxide, sodium hydroxide, alkali metal hydroxides such as sodium hydroxide, alkali metal carbonates such as sodium carbonate and potassium carbonate, and the like are used.
- this reaction involves the reaction of alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, nitriles such as acetonitrile, N, N-dimethylformamide,
- alcohols such as methanol and ethanol
- ethers such as dioxane and tetrahydrofuran
- aromatic hydrocarbons such as benzene, toluene and xylene
- nitriles such as acetonitrile
- N, N-dimethylformamide The reaction can also be carried out in an inert solvent such as amides such as N, N-dimethylacetamide and sulfoxides such as dimethyl sulfoxide.
- the reaction temperature is usually about 10 to about 200 ° C., preferably about 50 to about 100.
- the reaction time is generally about 30 minutes to about 24 hours, preferably about 1 to about 6 hours.
- the compound (V) or a salt thereof is generally used in an amount of about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of the compound (vr) or a salt thereof.
- This reaction is usually carried out in the presence of a base.
- a base examples include alkali metal hydrides such as sodium hydride and potassium hydride, alkali metal alkoxides such as sodium methoxide and sodium methoxide, and water.
- Alkali metal hydroxides such as sodium oxide and potassium hydroxide, and alkali metal carbonates such as sodium carbonate and potassium carbonate are used.
- this reaction involves the reaction of alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, nitriles such as acetonitrile, N, N-dimethylformamide,
- the reaction can also be carried out in an inert solvent such as amides such as N, N-dimethylacetamide and sulfoxides such as dimethyl sulfoxide.
- the reaction temperature is usually about 10 to about 200 ° C, preferably about 50 to about 100 ° C.
- the reaction time is generally about 30 minutes to about 24 hours, preferably about 1 to about 6 hours.
- the compound (VII) or a salt thereof is generally used in about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of the compound (VI) or a salt thereof.
- This reaction is usually carried out in the presence of a base.
- a base examples include alkali metal hydrides such as sodium hydride and potassium hydride, alkali metal alkoxides such as sodium methoxide and sodium ethoxide.
- Alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, and alkali metal carbonates such as sodium carbonate and potassium carbonate are used.
- this reaction involves the reaction of alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, nitriles such as acetonitrile, N, N-dimethylformamide,
- the reaction can also be carried out in an inert solvent such as amides such as N, N-dimethylacetamide and sulfoxides such as dimethyl sulfoxide.
- the reaction temperature is generally about 10 to about 200 ° C, preferably about 50 to about 10 ° C.
- the reaction time is generally about 30 minutes to about 24 hours, preferably about 1 to about 6 hours.
- the compound (VII) or a salt thereof is generally used at about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of the compound (VIII) or a salt thereof.
- this reaction is carried out in alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, nitriles such as acetonitrile, N, N-dimethylformamide,
- the reaction can also be carried out in an inert solvent such as amides such as N, N-dimethylacetamide and sulfoxides such as dimethyl sulfoxide.
- the reaction temperature is usually about 10 to about 200, preferably about 50 to about 100 ° C.
- the reaction time is generally about 30 minutes to about 24 hours, preferably about 1 to about 6 hours.
- the thus-obtained compound of the present invention can be converted into a salt according to a conventional method when it is in a free form, and can be converted into a free form or another salt according to a conventional method when a salt is formed.
- the thus-obtained compound of the present invention or a salt thereof can be isolated and purified by a known means, for example, solvent extraction, liquid conversion, phase transfer, salting out, crystallization, recrystallization, chromatography, and the like.
- the compound of the present invention or a salt thereof contains an optical isomer
- the compound is split into R-form and S-form by ordinary optical resolution means. You can also.
- Examples of the salt of compound (I) include salts with inorganic salts (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.) and organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid) , Maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, methanesulfonic acid, benzenesulfonic acid, etc.).
- inorganic salts eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
- organic acids eg, acetic acid, formic acid, propionic acid, fumaric acid
- an inorganic base for example, an alkali metal or an alkaline earth metal such as sodium, potassium, calcium, magnesium, or the like;
- organic bases e.g., birds such as Toryechiruamin - C, - 3 Arukiruamin
- the starting compounds (II) and (IV) or salts thereof can be prepared, for example, by the method described in Journal of Medicinal Chemistry (J. Med. Chem.), Vol. 32, p. 583 (1998). It can be synthesized by a method according to it.
- the starting compound (III) or a salt thereof can be prepared, for example, according to the method described in Journal of Organic Chemistry (J. Org. Chem.) 39, 2143 (1974) or a method analogous thereto. Can be synthesized by
- the starting compound (V) or a salt thereof can be synthesized, for example, by the method described in JP-A-62-2739 or a method analogous thereto.
- the starting compounds (VI) and (VIII) or salts thereof can be synthesized, for example, by the method described in JP-A-3-223287 or a method analogous thereto.
- the starting compound (VII) or a salt thereof can be prepared, for example, by the method described in Journal of Chemistry (J. Med. Chem.) 38, 2472 (1995) or a method analogous thereto. Can be synthesized.
- each of the reactions of the present invention and each of the reactions for synthesizing the starting compound when the starting compound has an amino group, a carboxyl group, or a hydroxyl group as a substituent, these groups are generally used in peptide chemistry and the like.
- a protective group may be introduced, and the target compound can be obtained by removing the protective group as necessary after the reaction.
- Examples of the protecting group for the amino group include formyl, which may have a substituent,
- C Bok 6 alkyl Cal Poni Le (e.g., Asechiru, such as E chill carbonyl), full Enirukaruponiru, d - 6 alkyl one Okishikaruponiru (e.g., Metokishika Ruponiru, an ethoxy Cal Poni Le), phenylalanine O carboxymethyl Cal Poni le, c 7 one 1 0 Ararukiru - Carbonyl (for example, benzylcarbonyl, etc.), trityl, fluoryl or N, N-dimethylaminomethylene is used.
- Asechiru such as E chill carbonyl
- d - 6 alkyl one Okishikaruponiru (e.g., Metokishika Ruponiru, an ethoxy Cal Poni Le)
- phenylalanine O carboxymethyl Cal Poni le c 7 one 1 0 Ararukiru - Carbonyl (for example, benz
- substituents examples include a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), d- 6 alkyl monopropionyl (eg, methylcarbonyl, ethylcarbonyl, butylcarbonyl, etc.), and a nitro group.
- the number of substituents is about 1 to 3.
- carboxyl-protecting group examples include, for example, an optionally substituted C 6 alkyl (eg, methyl, ethyl, n-propyl, i-propyl, n-butyl, tert-butyl, etc.) , Phenyl, trityl or silyl are used.
- a halogen atom for example, fluorine, chlorine, bromine, iodine, etc.
- formyl for example, acetyl, ethylcarbonyl, butylcarponyl, etc.
- the number of groups is about one to three.
- Examples of the protecting group for the hydroxyl group include, for example, an optionally substituted C, -6 alkyl (eg, methyl, ethyl, n_propyl, i-propyl, n-butyl, tert-butyl, etc.) ), phenyl, C 7 -,.
- Aralkyl eg, benzyl, etc.
- formyl C-alkyl 6- hydroxyl-ponyl (eg, acetyl, ethyl Rukaruponiru etc.), phenylalanine O carboxymethyl Cal Poni Le, Benzoiru, C 7 -,.
- aralkyl monoluponyl for example, benzylcarbonyl, etc.
- pyranyl, furanyl, or silyl is used.
- substituents include a halogen atom (for example example, fluorine, chlorine, bromine, iodine, etc.), d-6 alkyl (e.g., methyl, Echiru, n- propyl, etc.), phenyl, C 7 -,.
- Aralkyl for example, benzyl
- a nitro group, etc. are used, and the number of substituents is about 1 to 4.
- a method for removing the protecting group a method known per se or a method analogous thereto is used.
- Compound (I) or a salt thereof or a prodrug thereof has excellent antiallergic action, antihistamine action, anti-inflammatory action, anti-PAF (platelet activating factor) action, eosinophil chemotaxis inhibitory action, and the like.
- Low toxicity acute toxicity: LD 50> 2 g / kg), so it can be used as a safe antiallergic agent for mammals (eg, human, mouse, dog, rat, mouse, etc.) .
- the compound (I) or a salt thereof or a prodrug thereof has an anti-histamine effect and an eosinophil chemotaxis-inhibitory effect, and is effective for allergic disease, inflammatory disease, skin disease, It can be used for treatment or prevention of respiratory diseases and the like.
- Compound (I) or a salt thereof or a prodrug thereof can suppress nasal resistance, sneezing, nasal secretion, itching of eyes, and inflammation of eyes. It is useful for treatment or prevention.
- Allergic diseases include allergic skin diseases (eg, eczema, eczema ⁇ dermatitis, contact dermatitis, pruritus, dry dermatitis, chronic juvenile rash, acute measles, prurigo, atopic dermatitis, etc.) , Allergic rhinitis, allergic conjunctivitis, irritable pneumonitis and the like.
- allergic skin diseases eg, eczema, eczema ⁇ dermatitis, contact dermatitis, pruritus, dry dermatitis, chronic juvenile rash, acute measles, prurigo, atopic dermatitis, etc.
- Allergic rhinitis allergic conjunctivitis
- irritable pneumonitis irritable pneumonitis and the like.
- Skin diseases include atopic dermatitis, eczema, eczema, dermatitis, contact dermatitis, pruritus, dry dermatitis, chronic juniper, acute juniper, prurigo, herpetic dermatitis, psoriasis, etc.
- Inflammatory skin diseases include asthma, eosinophilic pneumonia (PIE syndrome), and chronic obstructive pulmonary disease (COPD).
- Nasal allergy ⁇ Inflammatory diseases include allergic rhinitis, upper respiratory irritability, and hay fever.
- Eye allergic and inflammatory diseases include conjunctivitis (eg, allergic conjunctivitis, giant papillary conjunctivitis, contact blepharoconjunctivitis, etc.), catarrh in spring, and hay fever.
- conjunctivitis eg, allergic conjunctivitis, giant papillary conjunctivitis, contact blepharoconjunctivitis, etc.
- catarrh in spring hay fever.
- compound (I) or a salt thereof or a prodrug thereof may be used for conjunctivitis (eg, allergic conjunctivitis, giant papillary conjunctivitis, contact blepharoconjunctivitis, etc.), spring catarrh, allergic rhinitis, pollinosis, etc. It is useful as an agent for preventing and treating allergic nasal and inflammatory diseases.
- conjunctivitis eg, allergic conjunctivitis, giant papillary conjunctivitis, contact blepharoconjunctivitis, etc.
- spring catarrh e.g, allergic rhinitis, pollinosis, etc.
- compound (I), a salt thereof, or a prodrug thereof has a reduced central translocation property as compared with a conventional condensed pyridazine compound.
- the route of administration of these prophylactic and therapeutic agents may be oral or parenteral.
- the preparation used in the present invention may contain, as an active ingredient, other pharmaceutical ingredients other than compound (I) or a salt thereof or a prodrug thereof.
- Such pharmaceutically active ingredients include anti-asthmatics (eg, theofilin, propoterol, ketotifen, azelastine, seratrodast, etc.), anti-allergic agents (eg, ketotifen, terfenadine, azelastine, epinastine, etc.), Examples include inflammatory agents (eg, diclofenac sodium, ibuprofen, indomethacin, etc.), antibacterial agents (eg, cefixime, cefdinir, ofloxacin, tosfloxacin, etc.), antifungal agents (eg, fluconazole, itraconazole, etc.).
- anti-asthmatics eg, theofilin, propoterol, ketotifen, azelastine, seratrodast, etc.
- anti-allergic agents eg, ketotifen, terfenadine, azelastine, epinastine, etc
- dosage forms include, for example, nasal drops, eye drops, aerosols, eye ointments, plasters, suppositories, troches, cataplasms, liniments, sustained-release preparations, sustained-release preparations, etc. Used.
- nasal drops are used for the prevention and treatment of allergic rhinitis and hay fever.
- Eye drops are suitable for the prevention and treatment of conjunctivitis such as conjunctivitis conjunctivitis, giant papillary conjunctivitis, contact blepharoconjunctivitis, and catarrh in spring.
- preparations are prepared according to a conventional method using additives generally used for pharmaceutical preparations.
- eye drops can be manufactured according to the method described in the general rules of preparations of the Japanese Pharmacopoeia.
- additives used in the nasal drops and eye drops of the present invention include buffers, stabilizers, thickeners, suspending agents, preservatives (preservatives), isotonic agents, and dissolution aids. Agents, PH regulators, fresheners, etc. are used.
- Buffers include, for example, sodium hydrogen phosphate, sodium dihydrogen phosphate, crystalline sodium dihydrogen phosphate, boric acid, borax, sodium carbonate, sodium L-dalformate or combinations thereof, weak acids, weak bases Alternatively, a salt thereof or a combination thereof is used.
- Stabilizers include, for example, sodium sulfite, sodium bisulfite, sodium metabisulfite, sodium thiosulfate, Rongalit, thioglycerol, thioglycolic acid, thiolactic acid, cysteine, dalyuthione, thioacetic acid, methionine, Compounds such as thiosorbitol, thioglucose, thiourea, etc .; inorganic acids such as boric acid, borax, phosphoric acid, metaphosphoric acid, sodium carbonate, sodium bicarbonate and salts thereof; formic acid, oxalic acid, tartaric acid, citric acid, edetate Organic acids such as acids and salts thereof (eg, sodium edetate); acid amides such as acetoamide, methyl acetylacetamide, nicotinamide, urea, and valpital; urea derivatives; glycol, propylene glycol, glycer
- thickener or suspending agent examples include polyhydric alcohols such as glycerin and macrogol; saccharides such as sorbitol, mannitol, and sucrose; methylcellulose, carboxymethylcellulose, and hydroxypropylmethylcellulose.
- Preservatives include, for example, paraoxybenzoic acid esters such as propyl paraoxybenzoate and butyl paraoxybenzoate; parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben; benzalkonium chloride; Chlorhexidine dalconate; reversible soaps such as cetyl pyridium chloride; alcohol derivatives such as chlorobutanol, phenylethyl alcohol and benzyl alcohol; organic acids such as sodium dehydroacetate, sorbic acid and sodium sorbate.
- paraoxybenzoic acid esters such as propyl paraoxybenzoate and butyl paraoxybenzoate
- parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben
- benzalkonium chloride Chlorhexidine dalconate
- reversible soaps such as cet
- phenols such as parachloromethoxyphenol and parachloromethcresol
- organic mercury agents such as thimerosal, phenolmercuric nitrate, phenylmercuric borate, phenylmercuric acetate, and nitromethol
- An acid polymyxin B is used.
- tonicity agent for example, sodium chloride, calcium chloride, lithium chloride, concentrated glycerin, propylene glycol, mannitol, sucrose and the like are used.
- solubilizers examples include polyvinylpyrrolidone K30, macrogol 400, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, and triethanola. Min, sodium carbonate, sodium citrate and the like are used.
- pH adjuster for example, sodium hydroxide or the like is used.
- cooling agent for example, 1-menthol, d1-camphor and the like are used.
- the nasal drops of the present invention can be produced as a solution or suspension using the above-mentioned components by a known method, for example, using a production machine. It can also be used as a powder formulation by triturating with an appropriate excipient such as lactose. Specifically, the above-mentioned components are uniformly dissolved and suspended, or the powdered preparation is generally used in a pressurized type (mechanical pump), pressure type (aerosol), squeeze type, inhalation type and the like. It can be supplied as a product by filling it into a nasal administration device.
- the content of compound (I) or a salt thereof or a prodrug thereof varies depending on the form of the preparation, but is usually about 0.001 to about 30% by weight, preferably about The content is about 0.01 to about 10% by weight, and more preferably about 0.05 to about 2% by weight.
- the dosage of these preparations varies depending on age, body weight, symptoms, route of administration, frequency of administration, etc.
- the active ingredient compound (I) or its compound Salt or a prodrug thereof
- the active ingredient usually about 0.001 to about 3 Omg / human, preferably about 0.01 to about 10 mg human, more preferably about 0.05 to about 2 mg human per day. It is good to nose once or twice.
- 0.001 to about 3 Omg of the active ingredient (compound (I) or a salt thereof or a prodrug thereof) per day is generally used for humans, preferably about 0.01 to About 10 mgZ human, more preferably about 0.05 to about SmgZ human, should be instilled once or twice a day.
- the present invention will be more specifically described with reference examples, examples, and experimental examples, but the present invention is not limited thereto.
- the detection of the fraction containing the target substance in the reference example was performed under observation by TLC (Thin Layer Chromatography, thin layer chromatography).
- TLC Thin Layer Chromatography, thin layer chromatography
- the powder X-ray diffraction analysis was measured as follows.
- Step A Production of 6- (3-hydroxypropylamino) [1,2,4] triazolo [1,5-b] pyridazine
- Step A Dissolve 3.9 ml of methyl 3-mercaptopropionate of 6- (3-bromopropylthio) [1,2,4] triazolo [1,5-b] pyridazine in 40 ml of methanol, and add 2N sodium methoxide solution 15 ml and l, 55 g of 6-chloro [1,2,4] triazolo [1,5-b] pyridazine were added, and the mixture was heated under reflux for 1 hour.
- Step A Production of 6- (2-hydroxyethylamino) [1,2,4] triazolo [1,5-b] pyridazine
- Step A Production of 6- (2-oxylanylmethoxy) [1,2,4] triazolo [1,5-b] pyridazine
- Reference example B 1 8 Preparation of 3- [4- (diphenylmethoxy) piperidino] -N-([1,2,4] triazolo [1,5-b] pyridazine-6-yl) propionamide
- Step A 3-chloro-N-([1,2,4] triazolo [1,5-b] pyridazine-6-yl) propionamide
- Step A Preparation of 2-bromo-N-([l, 2,4] triazolo [1,5-b] pyridazicy-6-yl) acetamide
- Step A Preparation of 2-([1,2,4] triazolo [1,5-b] pyridazine-6-yloxy) ethanol
- Process B Dissolve 275 mg of 2-([1,2,4] triazolo [1,5-b] pyridazine-6-yloxy) ethanol in tetrahydrofuran ⁇ , add 544 mg of N, ⁇ '-carbonyldiimidazole and stir at room temperature for 3 hours.
- 900 mg of 4- (diphenylmethoxy) piperidine and 0.53 ml of N-ethyldiisopropylamine were added thereto, and the mixture was further stirred at room temperature for 13 hours.
- the reaction solution was concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography, and eluted with ethyl acetate. The desired fraction was collected and concentrated to obtain 490 mg of the title compound.
- Reference example B 2 7 Preparation of 6- [3- [4- (diphenylmethoxy) piperidinocarbonyloxy] propoxy] [1,2,4] triazolo [l, 5-b] pyridazine
- Step A Production of 1- [3- (tert-butyldiphenylsilyloxy) propoxycarbon] -4- (diphenylmethoxy) piperidine
- Step B Production of 3- [4- (diphenylmethoxy) piperidinocarponyloxy] -topropanol
- Step A Production of 1- [3- (tert-butyldiphenylsilyloxy) propoxycarbonyl] -4- (diphenylmethyl) pidazine
- Step B Preparation of 3- [4- (diphenylmethyl) -topiperazinylcarbonyloxy] -toppropanol
- the mixture was subjected to force gel column chromatography, and eluted with ethyl acetate: methanol: triethylamine (50: 5: 1).
- the desired fraction was collected and concentrated, dissolved in 10 ml of ethyl acetate, concentrated by adding a solution of 263 mg of fumaric acid in 10 ml of methanol, and the residue was recrystallized from ethyl acetate to obtain 0.979 g of the title compound.
- 6-Chloro-2-phenyl [1,2,4] triazolo [1,5-13] pyridazine 365 mg and 4- (diphenylmethoxy) -topiperidinepropanamine 0.513 g are suspended in 8 ml of butanol and N 0.54 ml of -ethyldiisopropylamine was added, and the mixture was heated under reflux for 19 hours. Ice water and sodium hydrogen carbonate were added, and the mixture was extracted with ethyl acetate. The extract was washed with saturated saline and dried over magnesium sulfate.
- 6-[([l, 2,4] triazolo [1,5-b] pyridazine-6-yl) amino] -hexanol (1.64 g) is suspended in 40 ml of tetrahydrofuran and N-ethyldiisopropylamine (2.25) is suspended. g and methanesulfonyl chloride 2.0 g were added and stirred at room temperature for 5.5 hours. Ice water and sodium chloride were added, and the mixture was extracted with ethyl acetate-tetrahydrofuran (2: 1). The extract was washed with saturated saline and dried over magnesium sulfate.
- a mixture of 4.2 g of 4- (diphenylmethoxy) -topiperidinepropanamine and 1.76 g of ethyl 2- (6-chloroimidazo [1,2-b] pyridazin-2-yl) -2-methylpropionate is 190- Stir at 200 ° C for 3.5 hours. After cooling, water was added, and the mixture was extracted with ethyl acetate. The extract was washed with saturated saline and dried over magnesium sulfate. After concentration under reduced pressure, the residue was subjected to silica gel column chromatography, and eluted with ethyl acetate: methanol: triethylamine (100: 5: 1).
- tert-butyl 2- (6-chloroimidazo [1,2-b] pyridazin-2-yl) -2-methylpropionate was added, and the mixture was stirred at room temperature for 8 hours. Ice water was added, extracted with ethyl acetate, and the extract was washed with brine and dried over magnesium sulfate. After concentration under reduced pressure, the residue was subjected to silica gel column chromatography, and eluted with ethyl acetate: methanol: triethylamine (195: 5: 1).
- [1,5-b] pyridazine (540 mg) was added, and the mixture was heated under reflux for 3 hours. After cooling, ice water was added, extracted with ethyl acetate, and the extract was washed with saturated saline and dried over magnesium sulfate. After concentration under reduced pressure, the residue was subjected to silica gel column chromatography, and eluted with dichloromethane: ethyl acetate: methanol (10: 10: 1). Collect the desired fractions, collect the precipitated crystals by filtration, wash with ethyl ether, dry, and 730 mg of the product were obtained.
- Step A Production of 6- [2- (2-promoethoxy) ethylthio] [1,2,4] triazolo [1,5-b] pyridazine
- Process B 6- [2- (2-Bromoethoxy) ethylthio] [1,2,4] triazolo [1,5-b] pyridazine 890 mg and tri (diphenylmethyl) pidazine 740 mg in N, N-dimethylformamide 10 ml And added 490 mg of potassium carbonate and stirred at room temperature for 24 hours. Ice water was added, extraction was performed with ethyl acetate, and the extract was washed with saturated saline and dried over magnesium sulfate. After concentration under reduced pressure, the residue was subjected to silica gel column chromatography and eluted with dichloromethane: methanol (10: 1).
- Step A Preparation of 6- (6-bromohexylthio) -7-methyl [1,2,4] triazolo [l, 5-b] pyridazine
- Step A Preparation of 6- [2- (2-bromoethoxy) ethylthio] -7-methyl [1,2,4] triazolo [1,5-b] pyridazine
- Step A Preparation of 6- [2- (2-bromoethoxy) ethylthio] -7-isopropyl [1,2,4] triazolo [1,5-b] pyridazine
- Step A Production of 6- [2- (2-bromoethoxy) ethylthio] -7-tert-butyl [1,2,4] triazolo [l, 5-b] pyridazine
- the extract was washed with saturated saline and dried over magnesium sulfate. After concentration under reduced pressure, the residue was subjected to silica gel column chromatography and eluted with ethyl acetate. The desired fraction was collected and concentrated under reduced pressure. The residue was dissolved in 10 ml of ethanol, 476 mg of fumaric acid was added, and the mixture was concentrated again. The residue was crystallized by adding ethyl acetate, collected by filtration, washed with ethyl acetate, and dried to obtain 1.05 g of the title compound.
- the desired fraction was collected and dissolved in 20 ml of ethyl acetate, and a solution of 358 mg of fumaric acid dissolved in 20 ml of methanol was added thereto and concentrated. Acetone was added to the residue, and the precipitated crystals were collected by filtration, washed with acetone, and dried to obtain 0.901 g of the title compound.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002390919A CA2390919A1 (en) | 1999-11-11 | 2000-11-02 | Nose drop containing condensed pyridazine |
KR1020027006099A KR20020050275A (ko) | 1999-11-11 | 2000-11-02 | 융합 피리다진 유도체를 함유하는 점비제 |
AU10543/01A AU1054301A (en) | 1999-11-11 | 2000-11-02 | Nasal drops containing fused pyridazine derivatives |
EP00971740A EP1243271A1 (en) | 1999-11-11 | 2000-11-02 | Nasal drops containing fused pyridazine derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32107999 | 1999-11-11 | ||
JP11/321079 | 1999-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001034152A1 true WO2001034152A1 (fr) | 2001-05-17 |
Family
ID=18128584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/007719 WO2001034152A1 (fr) | 1999-11-11 | 2000-11-02 | Gouttes nasales contenant des derives de pyridazine condenses |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1243271A1 (ja) |
KR (1) | KR20020050275A (ja) |
CN (1) | CN1413112A (ja) |
AU (1) | AU1054301A (ja) |
CA (1) | CA2390919A1 (ja) |
WO (1) | WO2001034152A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004051600A (ja) * | 2002-07-24 | 2004-02-19 | Iyaku Bunshi Sekkei Kenkyusho:Kk | 造血器型プロスタグランジンd2合成酵素阻害剤 |
WO2005077953A1 (ja) * | 2004-02-18 | 2005-08-25 | Banyu Pharmaceutical Co., Ltd. | 含窒素縮合へテロ芳香環誘導体 |
WO2006088246A1 (ja) * | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Gpr34受容体機能調節剤 |
JP2011524854A (ja) * | 2008-06-19 | 2011-09-08 | 大塚製薬株式会社 | レバミピドの医薬組成物 |
US8153789B2 (en) * | 2006-03-29 | 2012-04-10 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093878A1 (en) * | 2003-04-16 | 2004-11-04 | Alcon, Inc. | Use of fused pyridazine derivatives for treating dry eye disorders |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0316633A1 (de) * | 1987-11-13 | 1989-05-24 | ASTA Medica Aktiengesellschaft | Azelastin enthaltende Arzneimittel zur Anwendung in der Nase und/oder am Auge |
US5482939A (en) * | 1992-03-18 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Triazolopyridazine compounds, their production and use |
JPH10226648A (ja) * | 1997-02-17 | 1998-08-25 | Towa Yakuhin Kk | 水性点鼻剤 |
EP0865790A2 (en) * | 1993-09-21 | 1998-09-23 | Takeda Chemical Industries, Ltd. | Use of triazolopyridazine derivatives in the manufacture of a medicament for the treatment of atopic dermatitis |
WO1998049167A1 (en) * | 1997-04-25 | 1998-11-05 | Takeda Chemical Industries, Ltd. | Condensed pyridazine derivatives, their production and use |
JPH11240882A (ja) * | 1997-12-24 | 1999-09-07 | Takeda Chem Ind Ltd | 縮合ピリダジン誘導体、その製造法および用途 |
-
2000
- 2000-11-02 AU AU10543/01A patent/AU1054301A/en not_active Abandoned
- 2000-11-02 WO PCT/JP2000/007719 patent/WO2001034152A1/ja not_active Application Discontinuation
- 2000-11-02 CA CA002390919A patent/CA2390919A1/en not_active Abandoned
- 2000-11-02 EP EP00971740A patent/EP1243271A1/en not_active Withdrawn
- 2000-11-02 KR KR1020027006099A patent/KR20020050275A/ko not_active Withdrawn
- 2000-11-02 CN CN00817469A patent/CN1413112A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0316633A1 (de) * | 1987-11-13 | 1989-05-24 | ASTA Medica Aktiengesellschaft | Azelastin enthaltende Arzneimittel zur Anwendung in der Nase und/oder am Auge |
US5482939A (en) * | 1992-03-18 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Triazolopyridazine compounds, their production and use |
EP0865790A2 (en) * | 1993-09-21 | 1998-09-23 | Takeda Chemical Industries, Ltd. | Use of triazolopyridazine derivatives in the manufacture of a medicament for the treatment of atopic dermatitis |
JPH10226648A (ja) * | 1997-02-17 | 1998-08-25 | Towa Yakuhin Kk | 水性点鼻剤 |
WO1998049167A1 (en) * | 1997-04-25 | 1998-11-05 | Takeda Chemical Industries, Ltd. | Condensed pyridazine derivatives, their production and use |
JPH11240882A (ja) * | 1997-12-24 | 1999-09-07 | Takeda Chem Ind Ltd | 縮合ピリダジン誘導体、その製造法および用途 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004051600A (ja) * | 2002-07-24 | 2004-02-19 | Iyaku Bunshi Sekkei Kenkyusho:Kk | 造血器型プロスタグランジンd2合成酵素阻害剤 |
WO2005077953A1 (ja) * | 2004-02-18 | 2005-08-25 | Banyu Pharmaceutical Co., Ltd. | 含窒素縮合へテロ芳香環誘導体 |
AU2005212096B2 (en) * | 2004-02-18 | 2010-12-16 | Msd K.K. | Nitrogenous fused heteroaromatic ring derivative |
WO2006088246A1 (ja) * | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Gpr34受容体機能調節剤 |
US8153789B2 (en) * | 2006-03-29 | 2012-04-10 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions |
US8993562B2 (en) | 2006-03-29 | 2015-03-31 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions |
JP2011524854A (ja) * | 2008-06-19 | 2011-09-08 | 大塚製薬株式会社 | レバミピドの医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2390919A1 (en) | 2001-05-17 |
CN1413112A (zh) | 2003-04-23 |
KR20020050275A (ko) | 2002-06-26 |
EP1243271A1 (en) | 2002-09-25 |
AU1054301A (en) | 2001-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113286794B (zh) | Kras突变蛋白抑制剂 | |
CN113905785B (zh) | 囊性纤维化跨膜传导调节因子调节剂 | |
KR100389192B1 (ko) | 축합 피리다진 유도체, 그것의 제조 방법 및 용도 | |
WO2000023450A1 (fr) | Derives fusionnes de pyridazine, procede de preparation correspondant et utilisation de ces derives | |
RU2346945C2 (ru) | Производные n-гетероциклилметилбензамидов, их получение и их применение в терапии | |
EP1040103B1 (en) | Anilide derivative, production and use thereof | |
JP6986032B2 (ja) | Jak阻害剤としてのピロロピリミジン化合物の結晶 | |
JP4938012B2 (ja) | N(アリールアルキル)−1h−ピロロピリジン−2−カルボキサミド誘導体、その調製およびその治療目的使用 | |
CN107417683A (zh) | 苯并咪唑呼吸道合胞病毒抑制剂 | |
KR20180073682A (ko) | 피리미딘 유도체 및 그의 사용 | |
CZ374692A3 (en) | Proteolytic enzymes inhibitors based on saccharin derivatives | |
JPS63225374A (ja) | チアゾ−ル誘導体、その製造法およびその組成物 | |
CA3142002A1 (en) | Targeted protein degradation of parp14 for use in therapy | |
CA3061209A1 (en) | Compound used as autophagy regulator, and preparation method therefor and uses thereof | |
WO2006008874A1 (ja) | アミノチアゾール骨格を有するCdk4,6選択的阻害剤 | |
KR20230024886A (ko) | 항바이러스 1,3-다이-옥소-인덴 화합물 | |
CN104725295B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
CN103180312A (zh) | 用于治疗或预防因血清素、去甲肾上腺素或多巴胺的神经传导的降低所导致的紊乱的杂环化合物 | |
WO2001034152A1 (fr) | Gouttes nasales contenant des derives de pyridazine condenses | |
JPH06508146A (ja) | 炭素環および複素環式hivプロテアーゼ抑制剤 | |
WO1998052919A1 (fr) | Derives de phtalimide et produit pharmaceutique contenant ces derives | |
CN112979613B (zh) | 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途 | |
US8044066B2 (en) | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | |
TW200404067A (en) | New compounds | |
JP2961534B1 (ja) | 縮合ピリダジン誘導体、その製造法および用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AU AZ BA BB BG BR BY BZ CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2390919 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10129725 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027006099 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000971740 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008174695 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027006099 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000971740 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000971740 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020027006099 Country of ref document: KR |